Modulation of Adult Neurogenesis in the Olfactory Bulb in an Acute Mouse Model of Parkinson´s Disease by CHIU, Wei-Hua & Ries, V. (PD Dr.)
Aus der Klinik für Neurologie 
Geschäftsführender Direktor: Prof. Dr. med. Dr. h.c. W. H. Oertel 
des Fachbereichs Medizin der Philipps-Universität Marburg 
 
 
 
Modulation of Adult Neurogenesis in the Olfactory Bulb in an Acute 
Mouse Model of Parkinson's Disease 
 
 
 
Inaugural-Dissertation 
zur Erlangung des Doktorgrades der gesamten Humanbiologie  
Dr. rer. nat. 
dem Fachbereich Medizin der Philipps-Universität Marburg 
vorgelegt von 
 
Wei-Hua Chiu  
geb. in Kaohsiung, Taiwan 
Marburg, 2013
  
Angenommen vom Fachbereich Medizin der Philipps-Universität Marburg am: 26.11.2013 
Gedruckt mit Genehmigung des Fachbereichs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan: Prof. Dr. H. Schäfer 
Referent: PD Dr. V. Ries 
Korreferent: Prof. Dr. E. Weihe 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
          Meiner Familie 
 
  
	   Index	   	  
	   	  
1 
	  
I. Introduction	  ...................................................................................................................................	  1	  
1	   Parkinson's disease	  ..............................................................................................................................	  1	  
1.1	   History of Parkinson's disease	  ....................................................................................................................	  1	  
1.2	   Etiology and pathology of Parkinson's disease	  .....................................................................................	  2	  
1.2.1	   Etiology	  .......................................................................................................................................................................	  2	  
1.2.2	   Pathology	  ....................................................................................................................................................................	  3	  
1.3	   Therapy of Parkinson's disease	  ...................................................................................................................	  3	  
1.3.1	   Drug treatment	  ..........................................................................................................................................................	  5	  
1.3.2	   Surgery	  ........................................................................................................................................................................	  6	  
1.4	   From pathology to pre-clinical symptoms	  ..............................................................................................	  7	  
1.5	   Olfactory dysfunction in PD	  ........................................................................................................................	  9	  
1.5.1	   The olfactory system	  ..............................................................................................................................................	  9	  
1.5.2	   Sensory transduction in the OB	  ........................................................................................................................	  10	  
1.5.3	   Clinical and experimental studies	  ....................................................................................................................	  12	  
2	   Adult neurogenesis	  .............................................................................................................................	  14	  
2.1	   History of adult neurogenesis	  ..................................................................................................................	  14	  
2.2	   Neurogenesis in the adult brain	  ...............................................................................................................	  14	  
2.3	   Regulation of adult neurogenesis	  ............................................................................................................	  16	  
2.3.1	   Dopaminergic control	  ...........................................................................................................................................	  16	  
2.3.2	   Intrinsic transcriptional factors	  .........................................................................................................................	  17	  
2.4	   Adult neurogenesis and olfactory function	  ..........................................................................................	  17	  
II. Aim of the study	  ......................................................................................................................	  19	  
III Materials and methods	  .........................................................................................................	  20	  
1	   Materials	  ...............................................................................................................................................	  20	  
1.1	   Chemicals	  .......................................................................................................................................................	  20	  
1.2	   Expandable materials	  ..................................................................................................................................	  21	  
1.3	   Buffer and solutions	  ....................................................................................................................................	  21	  
1.4	   Antibodies	  .......................................................................................................................................................	  23	  
1.5	   Experimental animals	  .................................................................................................................................	  23	  
1.6	   Software and equipment	  ............................................................................................................................	  24	  
2	   Methods	  ................................................................................................................................................	  25	  
2.1	   Histological study	  ........................................................................................................................................	  25	  
2.2	   Behavioral study	  ...........................................................................................................................................	  31	  
IV Results	  ........................................................................................................................................	  35	  
1	   Histological study	  ...............................................................................................................................	  35	  
1.1	   Effect of L-DOPA and Selegiline treatment on the nigrostriatal dopaminergic system 
following 6-OHDA lesion	  ....................................................................................................................................	  35	  
1.2	   Effect of L-DOPA and Selegiline on NPC proliferation in the SVZ	  ..........................................	  37	  
1.3	   Effect of L-DOPA and Selegiline on dopamine level in the OB	  .................................................	  37	  
1.4	   Modulation of NPC in the GCL of the OB following 6-OHDA lesion and subsequent L-
DOPA and Selegiline treatment	  ..........................................................................................................................	  38	  
1.5	   Modulation of NPC in the PGL of the OB following 6-OHDA lesion and subsequent L-
DOPA and Selegiline treatment	  ..........................................................................................................................	  41	  
1.6	   Modulation of neuronal proportion in the PGL following 6-OHDA lesion and subsequent 
L-DOPA and Selegiline treatment	  .....................................................................................................................	  43	  
1.7	   Changes in TUNEL staining following 6-OHDA lesion and subsequent L-DOPA and 
Selegiline treatment	  ................................................................................................................................................	  43	  
2	   Behavioral study	  .................................................................................................................................	  45	  
2.1	   Establishment of six animal models	  ......................................................................................................	  45	  
2.2	   Novel open field behavioral assessment	  ...............................................................................................	  45	  
2.3	   Olfactory discrimination test	  ....................................................................................................................	  49	  
2.4	   Effect of Selegiline treatment on olfactory discrimination test	  ....................................................	  52	  
  
	   Index	   	  
	   	  
2 
2.5	   Olfactory discrimination after withdrawal of Selegiline treatment	  .............................................	  54	  
V Discussion	  .................................................................................................................................	  58	  
1. Histological study	  ..................................................................................................................................	  58	  
2. Behavioral study	  ....................................................................................................................................	  63	  
VI. Summary	  ..................................................................................................................................	  67	  
VII. Abbreviations	  ........................................................................................................................	  69	  
VIII. References	  ............................................................................................................................	  72	  
IX. Acknowledgement	  ................................................................................................................	  83	  
X. Verzeichnis der akademischen Lehrer	  ..........................................................................	  84	  
XI. Ehrenwörtliche Erklärung	  ..................................................................................................	  85	  
	  
  
	   Introduction	   	  
	   	  
1 
 
I. Introduction  
1 Parkinson's disease 
1.1 History of Parkinson's disease  
 Motor signs of Parkinson's disease (PD) were reported the first time by James Parkinson 
(Fig. 1) in 1817, Royal College of Surgery, London. In his manuscript, An Essay on the 
Shaking Palsy, he described the clinical symptoms of 6 patients. 
 
  
 
 
 
 
Among 6 patients, he observed that tremor, rigidity, and walking problems were major 
complaints. Their age was 50-70 years. The onset of tremor of 2 of the patients in their upper 
limbs was at the age of 50 years. Parkinson also found a patient, who had difficulties to 
initiate his first step while intending to walk. After interviewing these patients, he noticed that 
this disease is progressive and that there is no prospective of relief (Parkinson, 2002). Later, 
Wilhelm von Humboldt, Jean-Martin Charcot and Alfred Vulpian added more clinical 
features after James Parkinson's first clinical description of these patients. The term 
"Parkinson's Disease" was the first time used by Jean-Martin Charcot and he was also the first 
physician to introduce the alkaloid atropine to treat PD patients. In 1912 Friedrich Heinrich 
Lewy described inclusion bodies in postmortem tissue, later named “Lewy bodies” as the 
pathological hallmark of Parkinson’s disease.  High doses of atropine to treat PD patients 
were very effective in the 1930s, but serious side effects were noticed thereafter. Atropine 
Fig. 1. James Parkinson (1755-1824)  
(The figure extracted from 
http://viartis.net/parkinsons.disease/history.htm) 
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was used for decades before the discovery of L-DOPA. In 1958, Arvid Carlsson defined the 
role of dopamine (DA) in the basal ganglia in reserpine treated rabbits. Oleh Hornykiewicz 
and Herbert Ehringer discovered the dopamine deficiency in PD patients in 1960. Oleh 
Hornykiewicz, Walther Birkmayer, Patrick Mcgeer and George Cotzias started to treat 
patients with L-DOPA after 1961. In 1969 the use of L-DOPA in combination with a dopa-
decarboxylase-inhibitor was introduced. Till today, L-DOPA is the most important drug (gold 
standard) in treating PD patients.  
1.2 Etiology and pathology of Parkinson's disease	   
Up to 5-10 % of the patients suffer from the disease before the age of 40, but the incidence 
increases steeply with age after the age of 60 (Wirdefeldt et al., 2011). The estimated 
incidence is about 160 per 100 000 person-years at the age of 65 years, in comparison to the 
range of 1.5 to 22 per 100 000 person-years in all age groups, and men are more frequently 
affected than women (Hirtz et al., 2007). Furthermore, the estimated number of PD subjects in 
most nations will be more than doubled within the next 20 years (Dorsey et al., 2007). 
1.2.1 Etiology 
Even though the etiology of PD is not well understood, both genetic susceptibility and 
environmental factors are very likely to be involved in the pathogenesis of the disease.  
Genetic studies have identified 11genes on 16 loci (PARK1 – PARK16) associated to PD. 
Two more loci – not yet associated to PD - have been discovered recently. These genes can be 
divided up in dominantly inherited mutations and recessively inherited mutations; The former 
include SNCA (PARK1/ PARK4), PARK3, UCH-L1 (PARK5), LRRK2 (PARK8), 
Omit/HtrA2 (PARK13), and the latter include Parkin (PARK2), PINK1 (PARK6), DJ-1 
(PARK7), ATP13A2 (PARK9), PLA2G6 (PARK14) and FBXO7 (PARK15) (Farrer, 2006). 
However, familial inherited PD accounts only for about 10-15% of all cases, 85-90% of PD 
patients are sporadic. 
Occupational and environmental toxin exposure is one of the risks to induce PD. For example, 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin) was indicated to cause chronic 
parkinsonian symptoms by damaging DA neurons in humans (Langston and Ballard, 1983). 
Natural toxins, such as rotenone, paraquat and dieldrin, are seen clinically to induce 
parkinsonian syndromes. Animal studies show that these natural toxins cause mitochondrial 
dysfunction, increased oxidative stress and aggregation of alpha-synuclein (a-syn) that result 
in a pathological alteration of the DA system (Wirdefeldt et al., 2011). Living style is also 
related to the incidence of PD. There is evidence that smoking and coffee consumption have a 
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negative association as risk factors of PD (Bronstein et al., 2009). Nicotine intake decreased 
the risk of PD proved in clinical studies (Tanner et al., 2002; Hancock et al., 2007) and 
experimental studies showed an anti-fibrillogenic activity against a-syn (Ono et al., 2007; 
Hong et al., 2009). Caffeine is a non-specific adenosine receptor antagonist (Schwarzschild et 
al., 2006) and drinking coffee was statistically associated with a decreased risk of PD (Ross et 
al., 2000). Despite nicotine and caffeine seem to provide compelling neuroprotective effects, 
more clinical and biomolecular studies are needed.  
1.2.2 Pathology 
Another pathological hallmark of PD is the loss of DA neurons in the substantia nigra (SN), 
which causes DA deficiency in the striatum. In postmortem studies, 50% to 77% of DA 
neurons are lost (Fearnley and Lees, 1991; Hirsch et al., 1988), leading to a 80% reduction of 
striatal DA content (Marsden, 1990). Among SN neurons, neuromelanin-pigmentated neurons 
are degenerating in PD. A 66% to 83% loss of pigmented neurons has been shown (Hirsch et 
al., 1988; Pakkenberg et al., 1991). The total number of pigmented neurons in PD patients 
shows a significant correlation with the duration of the disease process while the SN volume 
is equally maintained (Ma et al., 1997; Pakkenberg et al., 1991). In comparison to age-related 
control subjects, the loss of DA neurons is reduced by 64 % in the ventral SN, and the rate of 
neuronal loss of PD is exponential. In the first decade after disease onset, neuronal loss is 10 
times greater than that in age-matched controls. Moreover, distinct regions of neuronal loss in 
the SN can be distinguished from aging (Fearnley and Lees, 1991) and neuronal loss is not 
only determined spatiotemporally but also topographically.  
 
1.3 Therapy of Parkinson's disease  
Since DA was synthesized the first time by George Barger and James Ewens in 1910 in 
London, little progress was made in the next 30 years until Peter Holtz discovered AADC 
(aromatic-L-amino-acid decarboxylase, also called L-DOPA decarboxylase), which 
metabolizes L-DOPA to DA (Fig. 2). AADC in brain provides the formation of exogenous 
DA, as L-DOPA is able to cross the blood brain barrier (Fahn, 2008). In the early 1960s, 
Arvid Carlsson demonstrated that L-DOPA makes reserpinized akinetic rabbits immediately 
mobile. Moreover, he showed that the highest DA concentration is in the SN. 
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Fig. 2. Biochemical pharmacology of dopamine. (Adapted from Fahn et al. 2008.) 
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1.3.1 Drug treatment 
L-DOPA (L-3,4-dihydroxyphenylalanine) and DA agonists 
High doses of L-DOPA were given in the 1960s to treat PD patients until to 1969, then a 
combination with a peripheral dopa-decarboxylase-inhibitor was thus allowing to reach 
effectively brain L-DOPA level. L-Dopa is still considered as the gold standard in the 
management of the disease today. The point in time to start L-DOPA treatment is still a 
matter of debate. Fahn speculated that early use of L-DOPA supplies sufficient DA to activate 
DA neurons and their receptors, which can release the burden while remaining DA neurons 
try to compensate the partial neuronal loss. On the other hand, Cohen suggests that more 
exogenous DA might cause unnecessary free radicals that damage remaining DA neurons, 
therefore delayed use of L-DOPA would be favorable (Fahn, 2008). The results of a clinical 
study of the Parkinson Study Group showed that an earlier treatment of L-DOPA is beneficial 
for PD patients. However, FP-CIT-SPECT data in the same study contradicted the clinical 
results (Fahn, 2008). Recently, our group showed a correlated downregulation of striatal FP-
CIT signal and TH positive immunoreactivity of the striatum and the SN, in an acute model of 
6-OHDA lesioned mice after L-DOPA treatment, and the results suggested long term L-
DOPA treatment did not lead to DAergic overstimulation and the ensuing adaptive changes in 
the nigro-striatal pathway (Depboylu et al., 2013). 
Chronic L-DOPA monotherapy can relieve motor symptoms effectively, however, motor 
complications, such as fluctuation and dyskinesia, are a major challenge of L-DOPA therapy.  
A number of DA agonists have been developed to accompany L-DOPA to provide more 
stable DA concentrations in the brain. Dopamine agonists can also be used as monotherapy in 
the early stage of the disease to delay the introduction of L-DOPA. However, the agonists are 
usually less effective than L-DOPA and require the addition of L-DOPA within a few years. 
There are ergot derivatives and nonergoline agonists. As some of the ergot derivatives have 
shown severe side effects, like valvular fibrosis of the heart, nonergoline agonists are the first 
line drugs, e.g. pramipexole and ropinirole. DA agonists extended "on" state and reduced 
"off" state in combination with L-DOPA. Dyskinesia is also reduced by a combination of 
pramipexole, ropinirole or bromocriptine with L-DOPA. Besides assisting L-DOPA therapy, 
side effects of DA agonists require more consideration. Nausea, vomiting, postural 
hypotension, hallucination, somnolence and impulse control disorders are often seen in these 
patients (Antonini et al., 2009). 
  
	   Introduction	   	  
	   	  
6 
   
MAO-B (monoamine oxidase-B) inhibitor 
The action of MAO is to deaminate monoamines (Fig. 2). There are two types of MAO, the 
genetically distinct isoforms MAO-A and MAO-B. MAO-B is located dominantly in glial 
mitochondria and available to metabolize DA released into synaptic cleft (Fahn, 2008). Non-
selective MAO inhibitors were first designed to treat depression, however, due to the risk of 
the "cheese effect" (when tyramine is not degraded by MAO-A present in the gut and acts as a 
false transmitter to cause hypertension and other complications) these drugs are no longer 
available. Later the irreversible MAO-B inhibitor, Selegiline (formerly named deprenyl), was 
invented and provides a mild symptomatic effect (Fahn, 2008). One of Selegiline's 
metabolites, L-methamphetamine, inhibits the reuptake of extracellular DA, and indirectly 
elevates DA concentration in the brain (Magyar, 2004). Moreover, Selegiline delayed the 
need for L-DOPA treatment compared to the placebo treated group (Pålhagen et al., 2006). 
Two studies on Rasagiline, another MAO-B inhibitor, suggested a potential disease 
modifying effect in addition to its symptomatic benefit. However, it has not been possible to 
confirm a neuroprotective effect of both Selegiline and Rasagiline in clinical trials.  
 
1.3.2 Surgery 
 
The surgical procedure of thalamotomy was accidently developed in the 1940s. It had a 
surprisingly good effect on tremor. After discovering L-DOPA in the 1960s, surgery was 
abandoned. In the last 25 years, surgical treatment is again a clinical treatment option of PD 
because of three major reasons: Urgent need for treatment of side effects from drug therapy, 
more knowledge of DAergic circuitry from primate models, and the fast developing technique 
of image tools, such as MRI and CT scan (Rascol et al., 2011). 
 
Deep brain stimulation (DBS) 
 
David Marsden once said, DBS is the second miracle in the treatment history of PD after the 
L-DOPA invention. The dysregulated basal ganglia circuitry results from hyperactivity of the 
globus pallidus internus (GPi), which is mediated by a loss of inhibitory input and by an 
enhanced excitatory input via indirect DA pathways in primates (Rascol et al., 2011). The 
principle of DBS is to reduce the hyperactivity in the GPi or subthalamic nucleus (STN) by 
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applying high frequency stimulation (HFS) with the implantation of intracranial electrodes. 
Indeed, DBS is dramatically effective on motor symptoms of PD. Moreover, patients can get 
up to a 50% dose reduction of L-DOPA, whereby fluctuation and dyskinesia decrease (Rascol 
et al., 2011). However, the cost of surgery and hardware, patient selection, surgical 
complications, and psychosocial maladjustment need further evaluation.    
 
Cell transplantation and gene therapy 
Transplantation of human fetal mesencephalic DA cells or stem cell-derived DA cells into 
putamen have not yet been established in clinical routine use in the treatment of PD. 
However, cell replacement is possibly feasible. Standardization of transplanted cells, 
knowledge to rebuild the DA pathway, prevention of tumor-genesis, and appropriate patient 
selection are required (Lindvall and Kokaia, 2010). As in PD a number of different neurons 
degenerate in the peripheral and central nervous systems, cell replacement might only be 
beneficial for some of the symptoms (Poewe, 2009). Besides cell replacement, gene therapy 
might become a useful tool to treat the disease. Stereotaxic injection of adeno-associated virus 
(AAV) carrying the glutamic acid decarboxylase (GAD) gene in the STN or aromatic amino 
acid decarboxylase (AADC) in the putamen showed small but encouraging results in clinical 
pilot studies. Whether the delivery of neurturin as an analogon of glial derived neurotrophic 
factor (GDNF) will become a treatment option, needs to be evaluated in further clinical trials.  
 
1.4 From pathology to pre-clinical symptoms 
 Alpha-synuclein (a-syn) was first discovered in missense mutations in familial PD and it 
constitutes the major component of Lewy bodies (LB) and Lewy neurites (LN). These 
mutations cause a duplication or triplication of a-syn (Polymeropoulos et al., 1997; Spillantini 
et al., 1997). Braak and his colleagues performed immunohistochemistry of LB in 
postmortem studies to describe the stage of LB pathology in PD. The Braak staging scheme 
suggests that the initiation of LB pathology is in the dorsal nucleus of the vagal nerve, 
medulla oblongata and OB. In stage 2, LB and LN involve also the caudal raphe nuclei and 
reticular formation. LB pathology ascends dorsally and spreads gradually to the whole brain 
with disease progression. LB pathology in the SN is not found before stage 3 or 4, when 
motor symptoms start to develop. In the late stages, LB and LN pathology spread into specific 
nuclei of the thalamus and many prefrontal association fields (Braak et al., 2003).  
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Given the fact that premotor symptoms are widely accepted the Braak staging scheme 
provides a plausible framework to explain the observed evolution of the clinical features of 
PD (Kalaitzakis et al., 2009). The evidence of premotor symptoms preceding motor signs 
results from postmortem studies of incidental Lewy body disease (iLBD). Tyrosine 
hydroxylase (TH) staining shows intermediate levels of iLBD in the striatum and epicardial 
nerve fibers compared to controls and PD, and similar results in neuronal density of the SN. It 
is proposed that iLBD would very likely develop into PD if patients lived longer (Dickson et 
al., 2008). Even though the loss of SN neurons and DA deficiency in STR are hallmarks of 
PD, increasing evidence indicates that the pathological changes of this neurodegenerative 
disease occur widespread in the peripheral and central neural systems, affecting the 
dopaminergic, noradrenergic, serotoninergic and cholinergic system (Lim et al., 2009). The 
clinical symptoms, such as depression, hyposmia, constipation and rapid eye movement sleep 
behavior disorder (RBD) are therefore considered as premotor symptoms when the 
degeneration is not yet affecting the SN. Premotor symptoms can serve as risk factors or 
predicators for PD and could strengthen the search for potential biomarkers. Biomarkers for 
PD could enable us to apply disease-modifying therapies that prevent or stop disease 
progression before motor deficits occur in the future. 
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1.5 Olfactory dysfunction in PD 
Olfactory dysfunction was reported the first time in PD patients in 1975 (Ansari and Johnson, 
1975). Today, hyposmia is known as one of the premotor symptoms that can predate motor 
signs by several years and persist with the progression of PD. However, the cause of olfactory 
dysfunction in PD remains to be determined. It will require more information from basic and 
clinical research in order to understand and dissect the biological mechanisms underlying 
olfactory dysfunction in PD patients  
 
1.5.1 The olfactory system 
Offspring reproduction, maternal behavior, emotional responses, aggression, food selection 
and individual recognition are major functions of the olfactory system in mammals (Shipley 
and Ennis, 1996). When odor molecules (odorants) bind to receptors of olfactory sensory 
neurons (OSN) in the olfactory epithelium, the signals pass to the olfactory cortex via the 
main olfactory bulb (OB). In the OB, glomeruli are the units that refine signals from the OSN 
in the periglomerular cell layer (PGL). The signal is transmitted to output neurons such as 
mitral and tufted cells (M/T cells), confining conduction with local intrabulbar circuitries and 
centrifugal inputs (cholinergic, acetylcholinergic and serotoninergic projections from higher 
brain centers). The final processing occurs in the primary and accessory olfactory cortex 
corresponding to the piriform and the entorhinal cortex, respectively (Buck, 2000), and 
connecting to other neural systems in order to execute relevant functions (Carleton et al., 
2002; Shipley and Ennis, 1996).  
The other olfactory system, the vomeronasal organ (VNO), was found to play a role in social 
interaction in mammals. The VNO is enclosed in bony capsules on each side of the ventral 
nasal septum and connected by a narrow duct (Buck, 2000; Sanchez-Andrade and Kendrick, 
2009). Non-volatile odorants such as pheromonal information in urine, skin and reproductive 
secretions are recognized by the VNO that transmits signals by projecting to mitral cells in the 
accessory olfactory bulb , where signals are processed and carried to the olfactory cortex. The 
function of main OB and accessory OB are partially overlapping, being responsible for the 
conduction of volatile and non-volatile social scents (Sanchez-Andrade and Kendrick, 2009; 
Zufall and Leinders-Zufall, 2007).  
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1.5.2 Sensory transduction in the OB 
The topographical arrangement reveals that a given OSN projects to a given subset of 
glomeruli in the PGL (Fig. 3A-B) (Carleton et al., 2002; Buck, 2000). The signal relay in the 
OB is divided into two parts: the first part of the signal relay follows M/T cells receiving 
excitatory input from axons of the OSN and information via dendro-dendritic synapses with 
periglomerular cells of other glomeruli (Fig. 3A). There are two types of inhibitory 
transduction in the glomerulus. GABA mediated dendro-dendritic synapses inhibiting M/T 
cells and DA-mediated depression of synaptic transmission between mitral cells and OSN 
(Fig. 3B) (Aungst et al., 2003); the second part of the signal relay occurs in the deeper part of 
the OB. The dendrites of M/T cells extend into the external plexiform layer and construct 
reciprocal dendro-dendritic synapses with granular cells (mainly GABAergic neurons) in the 
granular cell layer  (Fig. 3A). The lateral inhibition and negative feedback from GABA-
mediated granular cells are used to restrain synaptic information in order to mediate 
transduction to M/T cells (Carleton et al., 2002; Hsia et al., 1999; Wachowiak and Shipley, 
2006). 
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Fig. 3. (A) The olfactory bulb receives signals from olfactory sensory nerves (Adapted from 
Shepherd and Greer 1990). (B) Synaptic transmission in the olfactory bulb (Adapted from 
Carleton et al. 2002) 
A. B. 
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1.5.3 Clinical and experimental studies 
Clinical studies 
Olfactory dysfunction is usually referred to hyposmia or anosmia. Olfactory detection, 
identification and discrimination can be evaluated by the "University of Pennsylvania Smell 
Identification Test" (UPSIT), another way to assess olfactory function would be the "Sniffing 
Sticks Test". More advanced methods, such as olfactory event-related potentials, diffusion-
weighted magnetic resonance imaging (MRI) and biopsy are also currently used in clinics 
(Lang, 2011).  
It has been shown that olfactory dysfunction is related to a central neural deficit. There was 
no correlation with proteins collected from the olfactory epithelium and hyposmia in PD 
patients (Witt et al., 2009). A population-based, longitudinal study demonstrated a clear 
relationship between olfactory dysfunction and iLBD pathology. Moreover, it has been shown 
that impaired olfactory function is often preceding the manifestation of motor deficits in PD 
by at least 4 years (Ross et al., 2008). There is evidence  that DA imbalance in the brain is not 
the only reason to cause olfactory dysfunction. For example, a positive correlation of 
hyposmia and cholinergic degeneration was shown in a study combining 11C-methyl-4-
piperidinyl propionate acetylcholinesterase brain positron emission tomography (PET) and 
UPSIT (Bohnen et al., 2010). Some reports suggested that the dysregulation of certain 
subtypes of neurons in the OB might also cause hyposmia in PD. LB pathology involves 
certain heterogeneous neurons in the OB, such as glutamate, calcium-binding, and P-positive 
cells that are relatively vulnerable to neurodegeneration (Ubeda-Bañon et al., 2010). An 
increased number of DAergic neurons was found in the PGL of PD in postmortem studies 
(Huisman et al., 2004; Mundiñano et al., 2011 ).  
 
Animal studies 
The use of animal models in PD is an important, alternative way to explore unknown disease-
related bio- or physiological mechanisms, in order to provide information regarding 
pathological alterations and therapeutic effects. Due to ethical issues it would not be possible 
to apply experimental procedures to patients.  
A transgenic mouse of a-syn overexpression using a Thy1-promoter showed some deficits of 
olfactory function. Thy1 a-syn overexpressing mice spent more time to find buried food 
pellets and spent less time to explore new scents compared to  control, suggesting an 
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impairment of olfactory function (Fleming et al., 2008). Another transgenic mouse of 
conditional a-syn overexpression under a tetracycline-controlled transactivator driven by 
CaMK-promoter showed a massive accumulation of a-syn in the OB and a decrease of 
neurogenesis in the OB (Marxreiter et al., 2009). Olfactory deficits were observed in two 
mouse models with a depletion of DA D2 receptors and the vesicular monoamine transporter 2 
(VMAT2), respectively (Taylor et al., 2009; Tillerson et al., 2006). In a knockout mouse 
model of Class VI alcohol dehydrogenase (Adh4) reduced smell ability was accompanied by 
alterations of DA metabolites in the OB (Belin et al., 2011). An intravenous administration of 
MPTP showed no impairment of olfactory function (Doty et al., 1992a), an intranasal infusion 
of low dose MPTP decreased the number of DA neurons and reduced the DA level in the SN 
and OB (Prediger et al., 2009). A number of reports showed consistent histological findings 
that the number of DA neurons in the PGL of the OB was increased in toxin-induced animal 
models (Belzunegui et al., 2007; O'Keeffe et al., 2009b; Winner et al., 2006; Yamada et al., 
2004), as found in the human OB (Huisman et al., 2004). An upregulation to overcome DA 
deficiency in toxin-induced animal models and PD patients would be a reasonable theory to 
explain the pathological condition.  
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2 Adult neurogenesis 
The subventricular zone (SVZ) in the lateral ventricle and the subgranular zone (SGZ) of the 
dentate gyrus (DG) supply neural progenitor cells (NPC) throughout the entire life of  
mammals. The OB is one of the few organs to receive newborn cells. NPC are renewing and 
replacing old cells in the adult OB. They migrate from the SVZ to the OB via rostral 
migratory stream (RMS). Despite the fact that adult-born neurons derived from NPC in the 
OB were described in a number of studies recently (Doetsch et al., 1999; Gage, 2000; 
Imayoshi et al., 2008), the impact on olfactory function is however poorly understood.    
 
2.1 History of adult neurogenesis 
Until the 1960s a widely accepted opinion was, that everything was fixed, and immutable in 
the central nervous system. Once neurons die, they cannot be regenerated. This concept was 
from Santiago Ramón y Cajal published in 1913. In the 1960s, Joseph Altman and colleagues 
used 3H-thymidine to label cells in the rodent brain and found a generation of newborn cells 
in the OB and hippocampus (Altman, 1969; Altman and Das, 1965). It was the first time that 
neurogenesis in the adult brain was proposed. However, Altman only showed morphological 
evidence of labelled cells. Kaplan and his colleagues confirmed that these labelled cells were 
newborn neurons by electron microscopy (Kaplan and Hinds, 1977). Nottebohm and 
coworkers further proved functional aspects on newborn neurons of the  songbird learning 
new songs in spring. This observation suggested that neurogenesis occurs in the adult brain 
and that these newborn neurons replaced dying neurons (Nottebohm, 2004). In the past 40 
years, adult-born neurons were studied and identified by high resolution image analysis, 
functional electrophysiology, genetic application of green fluorescence protein (GFP) and co-
expression of other cellular makers. Until today, it is well accepted that NPC reside mainly in 
the SVZ of the lateral ventricle and the SGZ of the dentate gyrus in adult mammals, also 
including humans (Suh et al., 2009). In neurogenic niches of the central nervous system, 
proliferating  cells migrate to a given destination to further differentiate into neurons and glia. 
 
2.2 Neurogenesis in the adult brain 
In the SVZ-RMS-OB system, NPC reside and proliferate in the SVZ (Fig. 4). They migrate 
en route to the OB tangentially where they differentiate into different interneurons passing 
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through the RMS. In the GCL of the OB, most NPC differentiate into GABAergic 
interneurons; whereas a small proportion of NPC become distinct interneurons in the PGL 
(Fig. 4) (Gage, 2000; Ming et al., 2011). The ablation of dividing cells by administration of 
anti-mitotic agents or genetic manipulation confirmed the relationship of two populations of 
different cell subtypes (Doetsch et al., 1999; Suh et al., 2009). Radial and non-radial 
morphology separates them as B cells and C cells (the transient state of A cells that migrate 
towards the OB) in the SVZ, respectively (Fig. 4.). The B cells have unique radial processes 
and a ramified structure at the end. The B cells also expresses GFAP, Nestin, Blbp and Sox2. 
The C cells have no radial processes and express Nestin and Sox2. It was shown that C cells 
in the SVZ were negative for GFAP, but positive for Dlx2, Mash1 and EGFR (Suh et al., 
2009).   
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2.3 Regulation of adult neurogenesis 
The regulation of adult neurogenesis indicates a number of factors that directly or indirectly 
determine the unidirectional process of NSC, which consists of cell proliferation, survival, 
phenotypic differentiation and cell death (Kempermann, 2011). The regulatory factors are 
numerous and heterogeneous. These complex factors are related to the progeny of NSC which 
raises two hypotheses regarding their characteristics: (1) NSC are homogenous but can be 
regulated by environmental or extrinsic factors, (2) NPC are heterogeneous with their potency  
intrinsically specified (Suh et al., 2009). Eventually, cell-fate decision may have an impact on 
functional behavior.  
 
2.3.1 Dopaminergic control 
Dopamine is secreted by DA neurons in the SN, ventral tegmental area (VTA) and 
hypothalamus. DA is an effective neurotransmitter governing the proliferation of NPC in the 
SVZ (Freundlieb et al., 2006). DA receptors are expressed in the NPC of the SVZ (Young et 
 
Fig. 4 The adult neurogenesis of the SVZ-RMS-OB. (modified from Ming. et al. 
2011.) 
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al., 2011). Moreover, the DAergic projections from SN and VTA regulate the survival and the 
proliferation of NPC (Freundlieb et al., 2006). D1- and D2-like receptors are located on NPC. 
In animal models of PD, a downregulation of the proliferation in the SVZ after dopamine 
depletion was shown (Baker et al., 2004; Höglinger et al., 2004; Winner et al., 2009; Winner 
et al., 2006). Also, a species related regulation was reported for D3 receptors (Baker et al., 
2005). The administration of L-DOPA and DA agonists reversed the downregulation caused 
by DA depletion in the nigrostriatal pathway (O'Keeffe et al., 2009a; O'Keeffe et al., 2009b). 
An impaired proliferation resulted in a reduced number of NPC and this reduction was 
reversible by exogenous DA via the activation of EGFR receptors (Höglinger et al., 2004; 
O'Keeffe et al., 2009b). The proliferation, migration, apoptosis, integration and differentiation 
of NPC is modified by DA in the SVZ-RMS-OB system.  
 
2.3.2 Intrinsic transcriptional factors  
How intrinsic regulators, such as transcriptional factors (TF) involved in the regulation of cell 
fate, determine adult-born neurons to become dopaminergic is still poorly understood. Pax6 
and Dlx2 are recently proposed as determinant TF for the specification and differentiation of 
NPC towards dopamine neurons in the PGL (Brill et al., 2008; Hack et al., 2005), and an 
upregulation of Pax6 was shown in the SVZ following  dopamine depletion (Winner et al., 
2006). Meis2 and Er81 are also expressed in a  subtype of dopamine neurons (Allen et al., 
2007). The internal fate of a newborn neuron is decided in advance even before they reach the 
PGL (Baker et al., 2001). Therefore, a single TF responding to environmental cues might 
interact with other TF when a physiological or pathological alteration is engaged. There is 
increasing evidence that TF might play an important role determining cell fate of NPC and 
phenotypic differentiation in the OB.  
 
2.4 Adult neurogenesis and olfactory function 
A potential function of newborn neurons in the OB is the maintenance of olfactory circuitries, 
sharping sensory perception, and supporting olfactory memory and learning (Lazarini and 
Lledo, 2011). The methods used to challenge newborn neurons are genetic manipulation, anti-
mitotic agents and irradiation. However, variant results are reported in distinct experimental 
paradigms and different behavioral approaches. On one hand, there has never been shown a 
direct role of adult neurogenesis in odor discrimination (Breton-Provencher et al., 2009; 
Imayoshi et al., 2008; Lazarini et al., 2009); on the other hand, newborn neurons seem to be 
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necessary to perform olfactory learning tests, for example, non-associated (animals learn 
about the relationship between two different stimuli) and associated odor discrimination 
(animals learn about the relationship between a stimulus and animals' own behavior) (Lazarini 
et al., 2009; Mouret et al., 2009; Rochefort et al., 2002; Sakamoto et al., 2011). Once NPC are 
selected to survive by learning, newborn neurons could change the physiology of the OB 
network. Furthermore, newborn neurons might retain a memory trace of the previous 
olfactory experience during an associative learning task (Lazarini and Lledo, 2011). In 
different olfactory learning tasks, it was shown that non-operant associative olfactory learning 
(pairing of a neutral stimulus with a reward) is independent of newborn neurons in the OB. In 
contrast, operant associative olfactory learning (acquisition of a specific behavior for getting 
the reward) increased the survival of newborn neurons and maintained the long-term memory 
(Lazarini and Lledo, 2011; Mandairon et al., 2011). Nevertheless, the relationship between 
the degree of adult neurogenesis and the complexity of discrimination learning tasks is not yet 
clearly identified.  
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II. Aim of the study 
In this project, we hypothesized that NPC can be modulated  by direct (L-DOPA) or indirect 
(Selegiline) dopaminergic stimulation, in an unilateral 6-OHDA mouse model of PD, which 
might provide a possible explanation of olfactory dysfunction frequently observed in PD 
patients.  
The goal of the study was to understand the modulation of cell survival and differentiation in 
the OB after anti-parkinsonian treatment with L-DOPA and/or Selegiline. In the OB, the cell 
fate of NPC might determine the generation of dopamine interneurons in the PGL after 
medication. Furthermore, we generated different animal models by 6-OHDA lesion and/or 
olfactory bulbectomy to further analyze the correlation of olfactory discrimination and 
dopamine depletion. We also examined if chronic Selegiline treatment can reverse hyposmia 
in a mouse model of PD.  
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III Materials and methods 
 
1 Materials 
1.1 Chemicals 
2% Rompun     Bayer, Leverkusen, Germany 
2M HCL     Roth, Karlsruhe, Germany 
30% H2O2    Roth, Karlsruhe, Germany 
3,3´-diaminobenzidine (DAB)  Serva, Heidelberg, Germany  
6-hydroxydopamine (6-OHDA)  Sigma, Steinheim, Germany 
ApopTag     Millipore, Temecula, USA 
(Apoptosis In Situ Detection Kit)   
Ascorbic acid     Merck, Darmstadt, Germany 
Avidin-biotin-peroxidase   Vector laboratories, Burlingame, USA 
Boric acid     Sigma, Steinheim, Germany 
BrdU      Sigma, Steinheim, Germany 
Chromium (III) potassium sulfate Roth, Karlsruhe, Germany 
Desipramine     Sigma, Steinheim, Germany 
Ethyl glycerol    Merck, Darmstadt, Germany 
Formamide     Sigma, Steinheim, Germany 
Gerlatin    Merck, Darmstadt, Germany 
Glycerol    Acros Organics, NJ, USA 
Isopropanol    Roth, Karlsruhe, Germany 
Isofluran    Baxter GmbH, Unterschleißheim, Germany 
Ketamin     Intervet, Neumünster, Germany  
L-DOPA (Madopar LT)  Roche, Grenzach-Wyhlen, Germany 
Normal goat serum   Vector Laboratories, Burlingame, USA 
Normal donkey serum  Millipore, Billerica, USA 
Paraformaldehyde   Roth, Karlsruhe, Germany 
Selegiline (R-(-)-l-deprenyl)   Sigma, Steinheim, Germany 
Sodium citrate    Sigma, Steinheim, Germany 
TUNEL dilution buffer   Roche Diagnostics, Indianapolis, USA 
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1.2 Expandable materials 
 
0.2 µm filter     Semadeni, Ostermundigen, Switzerland 
Bepanthen    Bayer, Leverkusen, Germany 
Betaisodona salbe   Mundi-Pharma GmbH, Limburg, Germany 
CryoPure tubes   Sarstedt, Nümbrecht, Germany 
Gloves (size M, powder free)  NOBA GmbH, Wetter, Germany 
Polyvinyl alcohol mounting medium  Sigma, Steinheim, Germany 
Needle (24G and 27G)  BD, Drogehede, Ireland 
Microsyringe, stainless needle, 33G  WPI, Sarasota, USA 
Microscope slides   Menzel-Gläser GmbH, Braunschweig, Germany 
Mounting gel     Corbit-Balsam, Kiel, Germany 
Cover slips    Menzel-Gläser GmbH, Braunschweig, Germany 
Pipette tips (10µl, 100µl and 1000µl) Eppendorf AG, Hamburg, Germany 
Syringe (1ml, 5ml and 10ml)  B/Braun, Melsungen, Germany 
Tissue freezing medium  Leica, Nussloch, Germany 
Wooden stick    OBI, Marburg, Germany 
1.3 Buffer and solutions 
0.2M Phosphate buffer  230 g Na2HPO4 •  2H2O 
     52.44 g NaH2PO4 • 2H2O  
     10 L distilled water   
0.1M Phosphate buffer saline  9 g NaCl 
     1 L 0.1M Phosphate buffer 
30 % Sucrose    15 g Sucrose 
     0.1 M PB 500 ml 
8 % Paraformaldehyde (PFA)  20 g PFA 
     241.66 ml distilled water at 60 °C 
Anti-freezer solution   5.18 g Na2HPO4 •  2H2O 
     1.57 g NaH2PO4 • 2H2O 
     300 ml Ethylglycerol 
     300 ml glycerol 
     400 ml distilled water 
SSC buffer     0.3 M NaCl 
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     0.03 M Sodium citrate 
Borate buffer (pH=8.5)   15.45 g Boric acid 
     450 ml distilled water 
     5 ml 10 N NaOH 
Gelatin Buffer    13 g Gelatin 
     0.18 g Chromium (III) potassium sulphate 
     300 ml distilled water 
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1.4 Antibodies 
Primary antibodies 
List of 
Antibodies 
Marker Dilution Source 
Rabbit anti-TH DA Neuron 1:1000 Thermo Scientific, Rockford, 
USA 
Rat anti-BrdU Base Analogue 1:500 Serotec,Düsseldorf,Germany 
Mouse anti-
NeuN 
Neuron 1:1000 Millipore, Billerica, USA 
Mouse anti-
PCNA 
Proliferation 1:500 Dako, Glostrup, Denmark 
Mouse anti-
digoxingennin 
Apoptosis 1:500 Abcam, Cambridge, UK 
 
Secondary antibodies 
List of Antibodies Dilution Source 
Biotin-SP-conjugated 
donkey anti-rabbit 
1:1000 Jackson ImmunoResearch 
Laboratories Inc., West 
Grove, USA 
Biotin-SP-conjugated 
donkey anti-mouse 
1:1000 Jackson ImmunoResearch 
Laboratories Inc., West 
Grove, USA 
Biotin-SP-conjugated 
donkey anti-rat 
1:1000 Jackson ImmunoResearch 
Laboratories Inc., West 
Grove, USA 
Cy™3-conjugated goat 
anti-mouse 
1:1000 Jackson ImmunoResearch 
Laboratories Inc., West 
Grove, USA 
CY™5-conjugated donkey 
anti-rabbit 
1:1000 Jackson ImmunoResearch 
Laboratories Inc., West 
Grove, USA 
Alexa 488 goat anti-rat 1:1000 Invitrogene™, Eugene, 
USA 
 
1.5 Experimental animals 
 A total number of 80 male C57BL/6 mice (Charles River, Sulzfeld, Germany), 10 weeks old 
in the beginning of the experiment, were used. The animals were housed in standard cages 
with ad libitum access to food and water at 23ºC with a 12:12 h light/dark cycle. All 
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experiment procedures were approved by the appropriate institutional governmental agency 
(Regierungspräsidium, Giessen, Germany). 
 
1.6 Software and equipment 
Cryostat microtome    Leica CM3050 S, Nussloch, Germany 
Digital camera    Olympus E-330, Japan 
Digital Luxmeter    Voltcraft, MS-1500, Taiwan 
Electric Driller    Proxxon, Nierbach, Germany 
Halogen light (300 longlife)  Schölly Fiberoptic GmbH, Germany   
HPLC BAS Liquid Chromatography Bioanalytical system, West Lafayette, USA 
HPLC computer system   Chromeleon™, Dionex, Germany 
Image J    http://rsbweb.nih.gov/ij/ 
Light microscope    Nikon Microphot-FX, Tokyo, Japan 
Laser confocal Microscope   Zeiss Axiovert 200M, Jena, Germany 
Pipetus    Hischmann Laborgeräte, Eberstadt, Germany 
Pump controller    Micro4TM, WPI, Sarasota, USA 
Prism 5.0c     GraphPad Software, San Diego, USA 
Stereotaxic frame    Kopf Instruments, Tujunga, CA 
StereoInvastigator software   v8, MicroBrightField, Magdeburg, Germany 
Thermometer    neoLab, Heidelberg, Germany 
Ultra Basic pH meter   Denver Instrument, Göttingen, Germany  
Ultra turrax     IKA, Bachofer, Reutlingen, Germany 
Viewer II video system   Viewer II, Bioserver, Bonn, Germany 
Water bath (GFL 1083)  Kobe, Marburg, Germany  
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2 Methods 
2.1 Histological study	  
Experimental design 
In a first set of experiments, 9 animals were perfused at three weeks post an unilateral 6-
OHDA injection in order to verify a decreased proliferation of NPC in the SVZ following 
dopamine depletion (Höglinger et al., 2004). Then, the following 5 groups of animals were 
established including: I. Normal control animals without treatment (n=11); II. 6-OHDA-
lesioned animals without treatment (n=11); III. 6-OHDA-lesioned animals treated with L-
DOPA (n=11); IV. 6-OHDA-lesioned animals treated with Selegiline (n=12); and V. 6-
OHDA-lesioned animals treated with a combination of L-DOPA and Selegiline (n=11). On 
day 19 to 21 following the lesion, 5-bromo-2´deoxyuridine (BrdU), was injected 
intraperitoneally (i.p.) every 12 hours (6 injections), before drug treatment was initiated for 4 
weeks. At the end of the treatment (7 weeks post 6-OHDA lesion), 4 animals of each group 
were taken for measurement of the dopamine concentration in the OB by high performance 
liquid chromatography (HPLC), while the others were perfused with 4% paraformaldehyde 
(PFA) for histological analysis (Fig. 5). 
0 3 7
Control
6-OHDA
6-OHDA+L-DOPA
6-OHDA+Selegiline
6-OHDA+L-dopa+Selegiline
BrdU
Histology/HPLC
 analysis
±6OHDA lesion
Start of treatment
(weeks)
Fig.1 Timelineig. 5. Experimental timeline 
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Unilateral 6-OHDA lesion 
Mice were deeply anesthetized by a mixture of ketamin (80 mg/kg) and 2% xylazin (4 mg/kg 
diluted in 0.9% NaCl), and placed in a stereotaxic frame. The noradrenergic system was 
protected from 6-OHDA toxicity by an i.p. injection of desipramine (25 mg/kg dissolved in 
0.9% NaCl) 20 minutes before surgery. A total amount of 4 µg 6-OHDA, dissolved in 2 µl 
0.9% NaCl/0.02% ascorbic acid was injected into the SN over 10 min (flow rate of 200 
nl/min) by pump. After the injection, the needle stayed in the brain for 5 more minutes before 
it was slowly retracted. All injections were performed using a microsyringe, stainless needle 
(33G). The coordinates of the injection were antero-posterior: +3.1 mm, medio-lateral: +1.2 
mm, and dorso-ventral: -4.2 mm, relative to bregma using a flat skull position. 
 
BrdU labeling 
To label proliferating NPC, mice received an i.p. injection of BrdU (50mg/kg dissolved in 
0.9% NaCl; Sigma). Animals received an injection twice a day for 3 consecutive days just 
before the start of drug treatment.  
 
Pharmacological treatment 
L-DOPA (1 mg/ml), and Selegiline (R-(-)-l-deprenyl) (0.1 mg/ml) were both administered via 
drinking water over 4 weeks. Drinking water was renewed every second day and the bottles 
were covered by aluminium foil to avoid rapid oxidation of L-DOPA. In order to achieve a 
sufficient intake of the drugs, all groups were water deprived for 12 hours every day (from 6 
pm to 6 am), and allowed to drink during the following 12 hours. Pilot studies showed that 
animals (n=5) drank approx. 3 ml of water (3.2 ± 0.1 ml) per day using this 12 hours of water 
deprivation protocol (Depboylu et al. 2013).  
 
Histology 
Mice were perfused transcardially with 0.1M PBS solution followed by 4% PFA in 0.1M PB 
(pH 7.4) using a pump at a rate of 15 ml/min. The brain was carefully removed and postfixed 
in 4% PFA, and transferred in 30% sucrose and stored at 4°C. Coronal sections were cut at 
30µm in 10 series using a cryostat microtom at -20°C, the sections were stored at -20ºC in 
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cryosolution (1:1:3 volume ratio of ethyl glycerol, glycerol and 0.1M PB buffer) until further 
processing.  
 
Immunohistochemistry 
Free-floating sections were washed three times in 0.1M PB to remove the cryoprotectant, 
thereafter quenched with 3% H2O2 and 10% methanol dissolved in 0.1M PB buffer. The 
sections were then preincubated in 5% normal donkey serum and 0.3% Triton X-100 in 0.1M 
PB buffer for 30 min, and incubated over night at 4°C with primary antibodies (rabbit anti-
TH, 1:1000; rat anti-BrdU, 1:500; mouse anti-NeuN, 1:1000; mouse anti-PCNA, 1:500; and 
mouse anti-Digoxigenin, 1:500). On the second day, sections were incubated in biotinylated 
species-specific secondary antibodies (donkey anti-rabbit/-rat/-mouse, 1:1000) or specific 
fluorochrome secondary antibodies (Cy3-conjugated goat anti-mouse; Cy5-conjugated 
donkey anti-rabbit, 1:1000) for one and two hours at room temperature, respectively. The 
sections treated with biotinylated antibodies were further incubated for one hour in avidin-
biotin-peroxidase solution. The protein was finally visualized by a 0.1M PB solution 
containing 5% 3,3´-diaminobenzidine (DAB) and 0.02% H2O2. The DAB stained sections 
were mounted on gelatin-coated glass slides, dried, and coverslipped using mounting gel. For 
fluorescence staining the sections were rinsed, mounted on gelatin-covered glass slides and 
directly coverslipped by polyvinyl alcohol mounting medium. 
 
Detection of BrdU-labeled nuclei  
Before incubation with the primary antibody, sections were incubated at 65ºC with a mixture 
of formamide and SSC buffer (1:1 by volume; 0.3M NaCl plus 0.03M sodium citrate) for 2 
hours, followed by 10 min incubation in SSC alone. Then, sections were incubated with 2M 
HCl, at 37ºC for 30 min. In order to neutralize the pH, sections were incubated 4 x 5 min with 
borate buffer (0.1M boric acid, pH=8.5).  
 
TUNEL staining 
TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining was used to detect apoptotic 
cells by enzymatically labeling 3’-OH termini of broken DNA in apoptotic cells. In Situ 
Detection Kit and modified protocols described previously were used for TUNEL labelling 
(Kuhn et al., 2005). Briefly, free-floating sections were first rinsed 3 x 10 min in 0.1M PB to 
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remove the cryoprotectant. They were then incubated in ascending and descending 
isopropanol solutions. After rinsing in 0.1M PB, the sections were incubated with TUNEL 
dilution buffer for 2 min, followed by a one-hour incubation at 37°C with terminal 
deoxynucleotidyl transferase (TdT, 1:3 dilution with TUNEL buffer, in order to reduce the 
background). Sections were finally incubated using “stop buffer” for 10 min at room 
temperature and rinsed in 0.1M PB solution. 
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DA concentration measurement 
To assess dopamine concentration in the OB, animals were sacrificed by rapid cervical 
dislocation one hour after the last drug treatment. The OB was removed from the skull, and 
dissected on an ice-cold petri dish. The tissue was homogenized in 300 µl 0.4N perchloric 
acid, and centrifuged at 20000 rpm for 1 min using ultra turrax. Following a 13000 g 
centrifugation for 20 min at 4°C, the supernatant was passed through a 0.2 µm filter. The 
dopamine concentration was finally measured in the final volume by HPLC with an 
electrochemical electrode. The data were analyzed by a HPLC computer system. 
 
Morphological analysis 
Striatal TH+ fiber density measurements 
In order to determine the extent of dopamine denervation following the 6-OHDA lesion, mean 
optical density was measured in the striatum. Briefly, images were captured using a digital 
camera (Olympus E-330) from four selected planes: 0.74 mm, 0.62 mm, 0.5 mm and 0.14 
mm, relative to bregma, and analysed using Image J software version 1.43r for Mac OS X 
platform (http://rsbweb.nih.gov/ij/). The striatum was outlined as previously described 
(Carlsson et al., 2011b). 
 
Determination of the number of TH+, PCNA+ and BrdU+ cells in the SN, SVZ and OB 
by stereologic analysis 
TH+, PCNA+ and BrdU+ cells were counted in the SN, SVZ and OB using 
StereoInvastigator software at 40x magnification. A fractionator probe was established for 
each section. Stereologic analysis was performed under blinded condition on coded slides. 
The criterion for counting an individual immunoreactive cell was the presence of its nucleus 
either within the counting frame or touching the upper and/or right frame lines (green), but 
not touching the lower and/or left frame lines (red). The total number of TH+ profiles in the 
SN and the number of PCNA+ profiles in the SVZ, respectively, was then determined by the 
StereoInvestigator program. The entire SN was delineated as previously described (Ries et al., 
2006). The SVZ was included in the rostral-to-caudal axis from 1.0 mm to 0.1 mm relative to 
bregma. In order to assess the number of BrdU+ cells in the GCL and PGL and TH+ cells in 
the PGL of the OB, 6 coronal sections were used corresponding to 5.18 mm, 4.88 mm, 4.58 
mm, 4.28 mm, 3.98 mm and 3.68 mm relative to bregma. The outline of the GCL is shown in 
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Fig. 10A, corresponding to the region inside the white dotted line, including the internal 
plexiform layer, but not the external plexiform layer and the mitral/tuft cell layer. The outline 
of the PGL is shown in Fig. 11A, as the region between the white dotted lines, corresponding 
to the area between the external plexiform layer and olfactory nerve layer. In order to estimate 
the number of TUNEL+ nuclei in the OB, 6 sections were used corresponding to 4.88 mm, 
4.58 mm, 4.28 mm, 3.98 mm and 3.68 mm and 3.38 mm relative to bregma. Here, the total 
number of TUNEL+ cells in the OB was counted. 
 
Co-localization of TH-, BrdU- and NeuN-positive cells in the OB 
In order to evaluate the frequency of neuronal and dopaminergic differentiation in the OB, 50 
BrdU+ cells of the GCL and PGL, respectively, were randomly selected from the same six 
sections as described above. These were analyzed for co-localization with either NeuN 
(neuronal differentiation) or TH (dopaminergic differentiation) using Laser confocal 
microscopy at 63x and 1 airy pinhole size. BrdU/NeuN double-labelled cells were evaluated 
in both the PGL and GCL, while BrdU/TH labelled cells were only evaluated in the PGL. 
Finally, the number of newly generated neurons and dopaminergic cells in the GCL and PGL 
were calculated as number of BrdU+ cells multiplied by the differentiation frequency. 
 
Statistics 
Multiple comparisons among groups were performed by one-way ANOVA followed by 
Tukey's post hoc analysis. The difference between two groups was analyzed by t-test. All data 
are presented as mean ± SEM. Significances were considered at p < 0.05 for all tests. 
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2.2 Behavioral study	  
Surgery 
Bulbectomy 
Male, 10 weeks old C57BL/6 mice were used for unilateral or bilateral bulbectomy. The mice 
were deeply anesthetized by a mixture of ketamin and 2 % xylazin, as described before. The 
head was placed in a stereotaxic frame. The skull above the OB was carefully removed. Then, 
the OB was carefully removed by surgical instruments either on one side (Left side) or 
bilaterally.   
 
Experimental design 
In total 6 different experimental groups of animals were used in the study: Control, unilateral 
6-OHDA injection (Uni), unilateral bulbectomy (UniBX), unilateral 6-OHDA injection plus 
contralateral bulbectomy (UniC), bilateral 6-OHDA injection (Bil6OHDA) and bilateral 
bulbectomy (BilBX) (Fig. 6A). The behavioral tests started at 3 weeks post surgery. The tests 
included  novel open field (NOF) assessment and olfactory discrimination test (ODT), and 
were performed at 3 weeks and 12 weeks post op, after 12 weeks of Selegiline treatment and 
4 weeks after Selegiline withdrawal (Fig. 6B).  
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Fig. 6. (A) Guideline of six different models. (B) Timeline of the behavioral test. X-axis 
indicates the number of weeks. The black arrow shows Selegiline treatment from  week 12 
to week 24. 
 
A. 
B. 
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Behavior Test 
Novel Open Field (NOF) 
 The novel open field test was performed in a dark room at 21 ± 1.0 °C. The size of each 
arena was 50 x 50 x 40 cm under a light intensity of 2.2-2.5 Lux. In order to allow animals to 
habituate with the room, they were brought and stayed in the room 20 min before the test. In 
every test trial, 8 animals randomly selected were tested for 30 mins. In between every trial, 
the arena was cleaned by 70 % ethanol to remove any scents. A Viewer II video system and 
software program were used to record the behavior of the animals in arena. The center of the 
area (36.5 cm x 36.5 cm) was delineated in the program. The parameters used were the 
tracklength and the time spent in the central area of the arena. 
 
Olfactory Discrimination Test (ODT) 
The test was described before with slightly modifications (Fleming et al., 2008). Briefly, 
wooden blocks (2.5 cm x 2.5 cm x 2.5 cm) were incubated in animal cages for 5 days before 
the test. During this time period, the bedding of the animal cages was not renewed in order to 
make wooden blocks carrying the animal's scent. On the day of the test, the wooden blocks 
were removed and put into a clean plastic bag sealed and labeled with corresponding animal 
number. Each animal was tested to discriminate the own odor from novel odors (male odor of 
a different colony or female odor) in the open field. To avoid any disturbances during the test 
wooden blocks were set up in the open field before the start. Then, animals were placed in the 
other half of the arena covered by a small lid (Fig. 7). Each animal had to perform a total of 6 
trials (5 min per trial) and 5 min intervals. In the first trial, two blocks carrying own odor were 
placed in the arena for habituation, and the animal was released by opening the lid from the 
other side to explore the entire arena (Fig. 7). In trial 2 to 5, animals explored a block carrying 
their own odor and one carrying a novel male's odor. In the 6th trial, a female's odor was 
replaced by the block carrying the other male's odor. All wooden blocks with novel odors 
were randomly selected from sealed plastic bags. Time spent on both wooden blocks were 
recorded and further analyzed.   
 
  
	   Materials	  and	  methods	   	  
	   	  
34 
  
 
 
 
 
 
 
Fig. 7. Position of the wooden blocks in the novel open field. Dashed lines represent 
the midline of the arena. Open box: control block (own odor); Closed box: 
experimental block (novel male or female odor) 
Arena Nr.1 Arena Nr.2
Arena Nr.3 Arena Nr.4
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IV Results 
1 Histological study 
1.1 Effect of L-DOPA and Selegiline treatment on the nigrostriatal 
dopaminergic system following 6-OHDA lesion 
At 7 weeks after a unilateral 6-OHDA injection into the SN, a histological analysis of the 
extent of the lesion was performed by TH-immunohistochemistry in all animals. TH-staining 
revealed an 88% loss of dopamine neurons in the SN on the lesioned side of non-treated mice 
(compared to the intact side). Similarly, a significant reduction of TH+ fibers was observed in 
the striatum of these animals on the 6-OHDA injected side (30.1 ± 7.4% of intact side) as 
measured by optical density. 
L-DOPA (1 mg/ml) and/or Selegiline (0.1 mg/ml) were given orally via drinking water for 4 
weeks, starting at 3 weeks post lesion. Neither L-DOPA nor Selegiline treatment resulted in a 
significant change of the number of TH+ neurons in the SN as compared to non-treated 
animals. Also TH+ fiber density in the striatum of the lesioned side did not show a significant 
difference compared to non-treated animals. There was also no effect on the number of TH+ 
neurons in the SN or TH+ fiber density in the striatum when the two drugs were combined 
(Fig. 8).  
  
  
	   Results	   	  
	   	  
36 
 
 
Fig. 8. TH and PCNA immunoreactivity in the nigrostriatal system and SVZ. At 7 weeks post 
6-OHDA injection, there was a significant loss of TH+ cells (One-way ANOVA followed by 
Tukey`s post-hoc test, n = 6-8, p < 0.001) and fibers on the lesioned side (D, F, G, H), as 
compared to the intact side (A, B, G, H). A loss of PNCA immunoreactivity was observed in 
the SVZ on the lesioned side, as compared to the intact side (C, E). Scalebar in A and B 
represents 500 µm and applies to A, B, D, F; scalebar in C represents 50 µm and applies to C, 
E.  
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1.2 Effect of L-DOPA and Selegiline on NPC proliferation in the SVZ 
Evaluating proliferation of NPC in the SVZ, a significant decrease of about 25% (3623 ± 178 
PCNA+ cells) was shown on the lesioned side compared to the intact side (4736 ± 229) 3 
weeks after 6-OHDA injection. Similar to the result at 3 weeks, at 7 weeks post 6-OHDA 
lesion the proliferation of NPC in the SVZ showed a significant decrease to 76.2 ± 3.5% of 
the intact side (Fig. 9A, B, F). Following four weeks of L-DOPA and/or Selegiline treatment, 
the number of PCNA+ cells in the SVZ was no longer significantly reduced in the treatment 
groups (L-DOPA: 93.8 ± 3.4% of intact side; Selegiline: 92.1 ± 4.3%; L-DOPA + Selegiline: 
83.9 ± 3.8%) as compared to non-lesioned control animals (103 ± 7.5%; Fig. 9A, C-F). 
 
 
Fig. 9. PCNA expression in the SVZ following 4 weeks of L-DOPA and/or Selegiline 
treatment in 6-OHDA lesioned mice. The 6-OHDA lesion caused a significant decrease in 
PCNA+ cells compared to controls at 7 weeks after 6-OHDA (A, B, F). Following 
administration of L-DOPA and/or Selegiline, the cell number was no longer significantly 
different from control (C-F). Number of cells on the lesioned side is represented in each 
column (in % of intact side). Scalebar in A represents 50 µm. (F: One-way ANOVA, n = 5-6, 
* p < 0.05, compared to control side; # p < 0.05, compared to 6-OHDA) 
 
1.3 Effect of L-DOPA and Selegiline on dopamine level in the OB 
Following 6-OHDA lesion, the dopamine content in the OB was decreased from 0.49 ± 0.03 
ng/mg tissue in control animals to 0.13 ± 0.02 ng/mg (Table 1.). Treatment with L-DOPA as 
well as Selegiline, however, increased the level to normal (0.50 ± 0.08 ng/mg and 0.42 ± 0.07 
ng/mg, respectively). When combining the two drugs, the dopamine level was significantly 
increased compared to non-lesioned controls (0.93 ± 0.18 ng/mg, p<0.05; Table 1.). These 
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HPLC data show that L-DOPA and Selegiline were effectively administered via drinking 
water. 
Groups  Dopamine (ng/mg tissue) 
Control 0.49 ± 0.03 
6-OHDA 0.13 ± 0.02 
6-OHDA + L-DOPA 0.50 ± 0.08 
6-OHDA + Selegiline 0.42 ± 0.07 
6-OHDA + L-DOPA + Selegiline 0.93 ± 0.18* 
 
Table 1. Dopamine concentration in the OB following 6-OHDA lesion and subsequent L-
DOPA and/or Selegiline treatment (One-way ANOVA followed by Tukey´s post-hoc test, n = 
4-6 per group, * p < 0.05, compared to control).  
 
 
1.4 Modulation of NPC in the GCL of the OB following 6-OHDA lesion 
and subsequent L-DOPA and Selegiline treatment 
Following dopamine depletion, the number of NPC in the GCL of the OB, as identified by 
BrdU immunostaining, was significantly decreased from 36960 ± 1414 cells in the control 
group to 28099 ± 1184 cells in the 6-OHDA group. The administration of Selegiline further 
enhanced this effect (20693 ± 1010), while in the L-DOPA group there was no significant 
decrease (33095 ± 2651; Fig. 10A-E, G), as compared to control animals. The combination of 
the two drugs showed an intermediate effect with a BrdU+ cell number of 26856 ± 2332 (Fig. 
10F, G). 
In order to further investigate the neuronal differentiation of the NPC in the GCL, 50 BrdU+ 
cells per group were randomly selected and sequentially analyzed for the expression of the 
neuronal marker NeuN by confocal microscopy (Fig. 10H). The percentage of BrdU and 
NeuN co-localizing cells was not changed significantly in any of the groups, as compared to 
control (Table 2). The total number of BrdU+/NeuN+ cells, however, varied in relation to the 
changes in the number of BrdU+ cells (Fig. 10I).  
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    GCL PGL 
Groups BrdU+ / NeuN+ BrdU+ / NeuN+ BrdU+ / TH+  
Control     95.4 ± 1.7      90.0 ± 2.7 16.9 ± 1.4 
6-OHDA 94.3 ± 1.2 90.5 ± 2.5 40.1 ± 2.6* 
6-OHDA + L-DOPA 95.6 ± 3.9 96.8 ± 1.4 47.4 ± 5.8* 
6-OHDA + Selegiline 90.8 ± 5.1 97.6 ± 1.0  18.8 ± 2.5#  
6-OHDA + L-DOPA + Selegiline 94.8 ± 1.0 87.6 ± 3.2 36.2 ± 2.3* 
 
Table 2. Percentage of BrdU+/NeuN+ in GCL and PGL, and BrdU+/TH+ in PGL (One-way 
ANOVA followed by Tukey`s post-hoc test, * p < 0.01, compared to control; # p < 0.0001, 
compared to 6-OHDA).  
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The number of adult-born neurons in the group treated with L-DOPA (31367 ± 4482) was not 
significantly different from the control group (35753 ± 4312). In contrast, the number after 
Selegiline treatment (18817 ± 3371) was significantly lower than that of the lesioned group 
without treatments. In addition, the number showed no significant change after treatment with 
a combination of L-DOPA and Selegiline (23659 ± 3367) compared to the lesioned animals 
without treatment (Fig. 10I).  
 
Fig. 10. Number of BrdU+ and BrdU+/NeuN+ cells in the GCL of the OB. There was 
a significant decrease in the number of BrdU+ NPC after 6-OHDA injection, as 
compared to controls (A-C, G). While Selegiline tended to further decrease the number 
of BrdU+ cells in the GCL, there was no significant decrease with L-DOPA (D, E, G). 
The number of co-labeled BrdU+/NeuN+ cells was counted in the GCL (H, I), 
showing a similar effect by the different treatment regimens with the difference 
between 6-OHDA and 6-OHDA + Selegeline reaching significance. Scalebars in A, B 
and H represent 500, 50 and 20 µm, respectively (G and I: One-way ANOVA followed 
by Tukey`s post-hoc test, n = 5-8, * p < 0.01, compared to controls;  # p < 0.05, 
compared to 6-OHDA). 
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1.5 Modulation of NPC in the PGL of the OB following 6-OHDA lesion 
and subsequent L-DOPA and Selegiline treatment 
The number of BrdU+ cells in the PGL of the OB was significantly reduced in the 6-OHDA 
lesioned animals (5024 ± 237) in comparison to controls (6522 ± 359). As in the GCL, this 
reduction in the PGL was restored by L-DOPA treatment for 4 weeks (6480 ± 488), while 
Selegiline further decreased the BrdU+ cell number in the PGL to 4347 ± 149 cells. The 
combination of L-DOPA and Selegiline increased the number of cells (5516 ± 188) compared 
to Selegiline only, but did not reach the effect of the L-DOPA treatment (Fig. 11A-G). 
As in the GCL, we assessed the neuronal fate by BrdU-NeuN co-localization in the PGL (Fig. 
11H-I). We again randomly selected 50 BrdU+ cells per group, and assessed the percentage 
of newborn NeuN+ neurons in control animals (Table 2). This percentage was not changed 
after a 6-OHDA lesion. Both L-DOPA and Selegiline treatment showed a trend to increase 
the percentage of newborn neurons, whereas the combination did not.  
Accordingly, the absolute cell number showed a significant decrease of newborn neurons 
(BrdU+/NeuN+ cells) in 6-OHDA lesioned animals in relation to controls. Similarly, a 
reduction was observed in the Selegiline only group. In contrast, L-DOPA treatment 
normalized the number of newborn neurons (Fig. 11I).  
In addition, we investigated the BrdU+ cells for their expression of TH (Fig. 11H, J; Table 
2). The percentage of TH+ cells was significantly higher following 6-OHDA, increasing from 
16.9 ± 1.4% in controls to 40.1 ± 2.6% in the 6-OHDA lesioned animals (Table 2). A 
significant increase was also seen in the group treated with either L-DOPA alone (47.4 ± 
5.8%), or the combination of L-DOPA and Selegiline (36.2 ± 2.3%). In the animals treated 
with Selegiline alone the percentage of TH+ profiles equaled the level of control animals 
(18.8 ± 2.5%). The number of newborn TH+ cells (2015 ± 169 cells) showed a significant 
increase in the 6-OHDA lesioned animals compared to controls (1107 ± 91; Fig. 11J). This 
number was significantly increased further after L-DOPA treatment (3022 ± 332). The 
Selegiline only group, showed a number of TH+ neurons in the PGL not different from 
control (814 ± 110; Fig. 11J). Combining the two drugs resulted in a number compared to 
that after 6-OHDA (2010 ± 172).  
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Fig. 11. Number of BrdU+, BrdU+/NeuN+ and BrdU+/TH+ cells in the PGL of the 
OB. Following 6-OHDA injection, the number of BrdU+ cells was significantly 
decreased as compared to controls (A-C, G). With L-DOPA there was no change 
compared to control, while Selegiline treatment tended to further decrease the number 
of BrdU+ cells (A, D, E, G). The combination of L-DOPA + Selegiline showed an 
intermediate response (A, F, G). Co-labeling of BrdU, NeuN and TH is shown in H. 
The number of BrdU+/NeuN+ cells (I) and BrdU+/TH+ cells (J) was evaluated in the 
PGL. The number of newborn neurons (BrdU+/NeuN+) showed a significant decrease 
after 6-OHDA injection, which was reversed by L-DOPA treatment (I). The number 
of newborn dopamine neurons (BrdU+/TH+) showed a significant increase or 
decrease following L-DOPA or Selegiline, respectively, compared to a 6-OHDA 
lesion alone (J). The scalebar in A represents 500 µm, in B 50 µm and in H 20 µm, 
respectively (G, I and J: One-way ANOVA followed by Tukey`s post-hoc test, n = 5-
8, * p < 0.05, compared to control;  # p < 0.05, compared to 6-OHDA). 
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1.6 Modulation of neuronal proportion in the PGL following 6-OHDA 
lesion and subsequent L-DOPA and Selegiline treatment	  
To better understand these changes in the ratio of newborn TH+ neurons in the PGL after a 6-
OHDA lesion and subsequent drug treatment, the number of newborn dopamine neurons 
(BrdU+/TH+) was divided by the total number of newborn neurons (BrdU+/NeuN+) in the 
PGL (Fig. 12C). This ratio was significantly higher in the 6-OHDA lesioned animals (44.6 ± 
3.0%), and this about 2-fold increase was sustained in the L-DOPA treated animals (46.7 ± 
5.0%), as compared to control animals (18.8 ± 1.7%). The Selegiline treated group in contrast 
had a normal rate (19.3 ± 2.6%), but not when Selegiline was combined with L-DOPA (40.5 
± 3.0%; Fig. 12C). 
This increased ratio of newborn TH+ neurons is reflected by an increased total number of 
TH+ cells in the PGL of the OB (Fig. 12A, B). The 6-OHDA injection alone and L-DOPA 
treatment increased the total number of TH+ cells to 37958 ± 1907 and 41468 ± 1864, 
respectively, compared to 29481 ± 960 in the control group. Selegiline normalized the cell 
number (27533 ± 1308). However, Selegiline, when given in combination with L-DOPA, was 
not able to counteract the increase seen by L-DOPA administration (37380 ± 1769; Fig. 12B). 
 
1.7 Changes in TUNEL staining following 6-OHDA lesion and 
subsequent L-DOPA and Selegiline treatment 
To investigate if Selegiline is regulating the number of newborn neurons in the OB by 
reducing the number of migrating NPC, TUNEL staining was performed (Fig. 12D-H). The 
6-OHDA lesioned group showed a non-significant trend to a decrease in the number of 
TUNEL+ cells, which was not changed by L-DOPA treatment, as compared to control (Fig. 
12H). In contrast, Selegiline alone and in combination with L-DOPA showed a highly 
significant upregulation of TUNEL+ cells in the OB.  
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Fig. 12. Total number and proportion of TH+ cells, and number of TUNEL+ cells in the PGL 
of the OB. The total number of TH+ neurons was increased by the lesion alone or with L-
DOPA treatment, as compared to controls. In comparison to the lesioned animals Selegiline 
decreased the number of TH+ neurons to the level of control (A, B). The ratio of newborn 
TH+ neurons to total newborn neurons in the PGL is significantly increased following 6-
OHDA lesion, and sustained by L-DOPA treatment. Selegiline in contrast normalized it (C). 
TUNEL+ cells, shown in (D) (indicated by an arrow with a high power inset), are mainly 
detected near the RMS (outlined region) and panel (E-G) indicate co-expression of 
TUNEL/BrdU by immunofluorescence. Selegiline alone and in combination with L-DOPA 
increased the TUNEL+ cells. A 6-OHDA-lesion with or without L-DOPA, in contrast tended 
to decrease the number of TUNEL+ cells (E). Scalebar in A represents 25 µm, in D 200 µm 
and in E 5 µm (B, C and H: One-Way ANOVA followed by Tukey posthoc test, n = 5-7, * p 
< 0.05, compared to control; # p < 0.01, compared to 6-OHDA; § p < 0.001, compared to 6-
OHDA + Selegiline). 
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2 Behavioral study 
2.1 Establishment of six animal models  
According to the finding in the histological part of this study, Selegiline normalizes the 
number of newborn DA neurons and the total number of DA neurons in the PGL of the OB in 
an acute 6-OHDA mouse model. In previous reports, odor discrimination seemed not to be 
affected while NPC were eliminated by antimitotic agents or genetic manipulation (Lazarini 
and Lledo, 2011). However, there is no report so far concerning the relationship between an 
increased number of DA neurons in the PGL and olfactory discrimination. In order to 
characterize whether Selegiline could improve olfactory discrimination, we established six 
different animal models to perform habituation-dishabituation of odor discrimination (by 
using male-female odor): (1) Control animals with sham operation (Control); (2) Unilateral 
intranigral 6-OHDA lesion (Uni); (3) Unilateral bulbectomy (UniBX); (4) Unilateral 
bulbectomy plus contralateral intranigral 6OHDA lesion (UniC); (5) Bilateral intranigral 6-
OHDA lesion (Bil6OHDA); (6) Bilateral bulbectomy (BilBX) (Fig. 6A).  
  
2.2 Novel open field behavioral assessment  
Novel open field (NOF) assessment was performed at 3 weeks, 12 weeks post operation and 
after 12 weeks of Selegiline treatment. To monitor general activity the duration (s) the 
animals spent in the central area of the area, a 36.5 cm x 36.5 cm square within the arena (50 
cm x 50 cm) and the tracklength (cm) were measured. The central tracklength showed the 
highest value in the control group (3738 ± 271). Tracklength was significantly lower in the 
BilBX group (2336 ± 283). The UniBX group (3058 ± 336) and the UniC group (2662 ± 200) 
had a slightly lower tracklength than control, but did not show a significant difference 3 
weeks post op (Fig. 13A). The time spent in the central area and the ratio of time spent in the 
central area to total time was lower in the Bil6OHDA group (305 ± 31, 19 % of total time) 
and the BilBX group (349 ± 58, 17 % of total time) compared to the control group (463 ± 32, 
26 % of total time), but there was no statistical significance between groups (Fig. 13B). 
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Fig. 13. Novel open field test. Tracklength and time spent in the central area. (A) 
Tracklength (cm) in the central area. (B) Time spent of total time the in the central area, 
the number on the bottom of each column represents the percentage of total time the 
animals spent in the central area (total test time 30 min) (One-way ANOVA, *p<0.05, n=5-
8).   
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At twelve weeks post op and before treatment, there was no statistical difference in central 
tracklength and time spent in the central area between groups. However, UniBX (3663 ± 526) 
and UniC (3760 ± 471) showed higher values of central tracklength compared to the control 
group (2722 ± 451), Uni (2320 ± 543) and BilBX (3015 ± 565) (Fig. 14A). For the time spent 
in the central area, there was a similar pattern regarding the different experimental groups 
(Fig. 14B).  
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Fig. 14. Novel open field test. Tracklength and time spent in the central area. (A) 
Tracklength (cm) in the central area. (B) Time spent in the central area, the number on 
the bottom of each column represents the percentage of total time the animals stayed in 
the central area (total test time 30 min) (One-way ANOVA, p>0.05, n=5-8).  
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After 84 days of Selegiline treatment in the NOF assessment there was no significant 
difference between groups regarding tracklength and duration spent in the central area (Fig. 
15). The Uni (3951 ± 452) and UniBX (3807 ± 543) groups showed higher values of the 
tracklength compared to the groups of control (2704 ± 446), the Bil6OHDA (2933 ± 427) and 
the BilBX (2817 ± 567) (Fig. 15A). The UniC group (518 ± 102, 29 % of total time) showed 
the longest duration spent in the central area compared to the shortest one in the Bil6OHDA 
group (399 ± 51, 22 % of total time) (Fig. 15B). 
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Fig. 15. Novel open field test. Tracklength and time spent in the central area. (A) 
Tracklength (cm) in the central area. (B) Time spent in the central area, the number on the 
bottom of each column represents the percentage of total time the animals stayed in the 
central area (total test time 30 min) (One-way ANOVA, p>0.05, n=5-8).  
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2.3 Olfactory discrimination test  
 In order to detect the time point of a beginning olfactory deficit in all models, we performed 
the olfactory discrimination test every 3 weeks. There was a significant increased duration of 
time spent on the experimental block in the 6th trial (female's odor) in comparison to the 5th 
trial (other male's odor) in all groups, except the BilBX group 3 weeks post op (Fig. 16). The 
time spent investigating the block carrying with the experimental odor in the 5th versus the 
6th trial is shown in Fig. 16, [percentage of time spent at the experimental block compared to 
the time spent on both blocks (%)]: Control: 44.96 ±	 18.86 (5th trial) versus 79.38 ± 9.30 (6th 
trial); Uni: 47.09 ±	 9.33 versus 76.90 ±	 20.93; UniC: 50.93 ±	 19.70 versus 73.39 ± 11.75; 
Bil6OHDA: 46.12 ± 24.80 versus 76.78 ± 15.36; UniBX: 47.99 ± 14.82 versus 72.64 ± 23.64; 
BilBX: 50.22 ± 25.71 versus 61.15 ± 10.60.  
The time spent on the experiment block in the 6th trial in comparison to the 5th trial was 
significantly increased in control, Uni and UniBX animals whereas UniC, Bil6OHDA and 
UniBX groups showed no significant difference at 12 weeks post op (Fig. 17). Control: 45.10 
± 28.04 versus 72.30 ± 12.94; Uni: 28.93 ± 12.79 versus 64.58 ± 19.79; UniC: 34.39 ± 17.19 
versus 48.15 ± 10.90; Bil6OHDA: 48.48 ± 25.40 versus 58.42 ± 22.88; UniBX: 41.11 ± 25.05 
versus 69.80 ± 11.16; BilBX; 37.07 ± 29.95 versus 46.32 ± 25.25. 
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Fig. 16. Olfactory discrimination test at 3 weeks in six experimental groups. X-axis 
represents the exposure to another male's odor (2nd-5th trial) and to female's odor 
(6th trial); Y-axis represents the percentage of time spent on the experimental block 
compared to the overall time spent on both blocks). *p<0.05, t-test (5th trial versus 
6th trial). 
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Fig. 17. Olfactory discrimination test at 12 weeks in six experimental groups. 
*p<0.05, t-test (5th trial versus 6th trial). 
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2.4 Effect of Selegiline treatment on olfactory discrimination test 
 After the appearance of an olfactory deficit observed at 12 weeks post operation in the groups 
of UniC and Bil6OHDA, a subcutaneous daily Selegiline injection was performed in all 
groups for 12 weeks. In the UniC, Bil6OHDA, and BilBX group, the time spent on the 
experimental block carrying female odor increased (Fig. 18). In the Bil6OHDA group, 
however, the increase in time spent on the experimental block in 6th trial did not show 
statistical significance. The percentage of time spent investigating the experimental odor 
compared to the time spent in total blocks: Control: 45.27 ±	 20.08 (5th Trial) versus 72.54 ± 
12.99 (6th Trial); Uni: 39.81 ± 10.84 versus 58.97 ± 17.88; UniC: 50.45 ± 5.50 versus 69.83 ± 
6.55; UniBX: 47.87 ± 14.81 versus 63.36 ± 10.72; Bil6OHDA: 35.98 ± 16.00 versus 57.94 ± 
19.15; BilBX: 25.01 ± 21.86 versus 68.29 ± 9.92. 
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Fig. 18. Olfactory discrimination test after 12 weeks of Selegiline treatment in six 
experimental groups. *p<0.05 and **p<0.01, t-test (5th trial versus 6th trial). 
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2.5 Olfactory discrimination after withdrawal of Selegiline treatment 
 To determine whether the improvement of olfactory function still continued after Selegiline 
treatment, treatment was terminated and the behavioral test was performed again 4 weeks 
after the withdrawal of Selegiline. Interestingly, comparing to the 5th and 6th trial, Uni, 
Bil6OHDA, UniC and BilBX no longer showed a significant increase in time investigating 
the experimental odor (Fig. 19). In control and UniBX, they showed an increase time spent on 
the experimental odor as shown in previous tests. Control: 28.26 ±	 19.52 (5th Trial) versus 
74.87 ± 15.41 (6th Trial), Uni: 49.15 ± 10.28 versus 59.95 ± 15.55, UniC: 42.99 ± 15.65 
versus 59.50 ± 20.26, UniBX: 38.00 ± 10.98 versus 65.31 ± 18.90; Bil6OHDA: 51.83 ± 23.36 
versus 61.30 ± 13.66; BilBX: 60.32 ± 19.71 versus 69.01 ± 21.60.  
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Fig. 19. Olfactory discrimination test 4 weeks after withdrawal of Selegiline in six 
experimental groups. *p<0.05 and **p<0.01, t-test (5th trial versus 6th trial). 
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To conclude in the olfactory discrimination test, only the BilBX group showed an olfactory 
deficit (red dash square in Fig. 20) at the time points 3 weeks post op and 12 weeks post op. 
The UniC group started to develop an olfactory deficit at 12 weeks post op (Fig. 20) After 12 
weeks of Selegiline treatment, the olfactory deficit seen in UniC and BilBX were reversed to 
normal. The olfactory deficit appeared again after 4 weeks of Selegiline withdrawal in UniC 
and BilBX. The control and UniBX maintained a normal olfactory function at all time points 
of the test.  
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Fig. 20. Summary of the olfactory discrimination test. White dash square represents 
animal spent most of the time on the position of the wooden block with the female 
odor; Red dash square represents animal did not prefer the wooden block with the 
female odor.  
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V Discussion 
1. Histological study 	  
In the current study, we demonstrate that L-DOPA and Selegiline show a similar 
modulation of NPC proliferation in the SVZ in an unilateral 6-OHDA mouse model 
of PD, but distinct modulation of the number of newborn TH+ neurons in the OB, 
most likely due to a differential regulation of their survival.  
An intranigral injection of 6-OHDA in rodents was first described and characterized 
by Ungerstedt et al. (Ungerstedt, 1968). Because of the electroactive properties of 6-
OHDA, 6-OHDA is rapidly oxidized in neurons to generate free radicals and 
hydrogen peroxidase, which induces neurodegeneration (Schwarting and Huston, 
1996). Besides the SN, the striatum and the median forebrain bundle (MFB) are also 
used to perform a 6-OHDA lesion in rodents (Alvarez-Fischer et al., 2008; Carlsson et 
al., 2011a; Deumens et al., 2002; Ungerstedt, 1968). The striatum and the MFB were 
not considered to inject 6-OHDA, in order to avoid physical damage caused by 
surgery, direct toxicity from 6-OHDA to NPC residing in the lateral wall of the 
ventricle, and a higher rate of mortality after 6-OHDA injection into the MFB of 
mice. In addition, an injection of 6-OHDA into the striatum and the MFB causes an 
inevitable lesion of VTA neurons, while injecting 6-OHDA into the SN causes a more 
specific lesion to SN neurons (Deumens et al., 2002; Kirik et al., 1998). Therefore, the 
SN was chosen for injection in our study.  
Following nigrostriatal dopamine depletion, the number of NPC was significantly 
decreased in the SVZ. Pharmacological restoration of dopaminergic transmission in 6-
OHDA lesioned mice restored proliferation of NPC to the level seen in control 
animals. This is in accordance with previous reports (Baker et al., 2004; Höglinger et 
al., 2004; O'Keeffe et al., 2009b). A partial recovery in the number of PCNA+ cell 
was also observed in Selegiline treated animals (alone or in combination with L-
DOPA). The proliferation of C cells located in the SVZ is stimulated by dopaminergic 
projection via D2-like receptors, (Höglinger et al., 2004). Furthermore, dopamine D2 
and D3 receptors are also expressed on migrating NPC (Van Kampen et al., 2004; 
Winner et al., 2009), and a lack of dopaminergic stimulation on these cells may lead 
to a decreased number, while increased dopamine receptor stimulation would increase 
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the proliferation of PCNA+ cells in the SVZ. Similar to L-DOPA, we show here for 
the first time that Selegiline alone can partly normalize proliferation of NPC in the 
SVZ. Selegiline, which is an irreversible MAO-B inhibitor, indirectly increases 
extracellular dopamine in the brain by reducing its degradation. In addition, its 
metabolite (R)-(-)-methylamphetamine is reported to inhibit the re-uptake and to 
promote the release of dopamine from the terminals (Magyar, 2004). Today, 
Selegiline is commonly used as anti-parkinsonian treatment, especially in the early 
stages of PD to delay the need for L-DOPA treatment, and in later stages combined 
with L-DOPA to reduce motor fluctuations in PD patients (Fernandez and Chen, 
2007; Lo and Jain, 2006; Pålhagen et al., 1998; The-Parkinson-Study-Group, 1993). 
The exact mechanism of Selegiline to increase the number of NPC in the SVZ after 
nigrostriatal lesion is unknown, but indirect dopamine receptor stimulation would be a 
plausible theory. 
Höglinger et al. showed in a postmortem study a significant downregulation of NPC 
proliferation in brains of PD patients as compared to control subjects. Consistently, 
O’Sullivan and colleagues investigated the role of dopaminergic treatment, 
confirming a positive impact of chronic L-DOPA administration on the number of 
NPC in the SVZ (O'Sullivan et al., 2011). Van den Berge et al. recently observed no 
change in the proliferation of NPC in the SVZ between control subjects, PD patients 
treated with L-DOPA, or patients with incidental Lewy body disease (LBD) without 
L-DOPA treatment (van den Berge et al., 2011). However, the cases with incidental 
LBD did not show a significant reduction in TH expression in the striatal area 
underneath the SVZ. Despite these controversial findings in human brains, rodent 6-
OHDA models of PD rather consistently show a downregulation of NPC proliferation 
in the SVZ after dopamine depletion. 
The NPC migrate from the SVZ to the OB where they differentiate into interneurons 
(Altman, 1969; Lois and Alvarez-Buylla, 1994). In order to better understand survival 
and fate of these cells following dopamine depletion, we analyzed the NPC in the OB, 
using BrdU labeling. In line with other investigators, the number of surviving BrdU+ 
NPC in PGL and GCL decreased after a 6-OHDA lesion (O'Keeffe et al., 2009a; 
O'Keeffe et al., 2009b). This may readily be explained by the evident downregulation 
of NPC proliferation in the SVZ. However, also here contradicting data have recently 
been published showing an increased survival of BrdU+ cells in the GCL and the 
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PGL (Sui et al., 2012), and an increase  in the PGL, but no change in the GCL 
(Winner et al., 2006), at 6 weeks post 6-OHDA injection. The time point of the first 
BrdU injection may explain these discrepancies. A decreased proliferation of NPC in 
the SVZ has been seen in rodent 6-OHDA models, three weeks post lesion at the 
earliest (Baker et al., 2004; Höglinger et al., 2004). As Winner et al. and Sui et al. 
administered the first BrdU-injection at day 7, as compared to day 21 in the study by 
O'Keefee, and day 19 in our study, there may not yet have been a definitive decrease 
in proliferation established in the SVZ in the former studies. BrdU injections at an 
earlier time point, as performed by Winner et al. and Sui et al., might therefore label 
proliferating NPC of a rather intact SVZ and miss to detect a decreasing number of 
BrdU+ cells in the OB. It is also worth noting, that NPC need about 30 days to 
migrate from the SVZ to the OB and to differentiate into interneurons (Lois and 
Alvarez-Buylla, 1994). In our study, the four week-treatment regimen of dopamine 
modulating drugs (L-DOPA and Selegiline) is within this time window. 
In order to further understand whether increased apoptosis is involved in the 
modulation of the survival of NPC following L-DOPA and Selegiline treatment, 
TUNEL staining was performed to evaluate the number of apoptotic cells in the OB. 
Our data clearly demonstrate that Selegiline alone or in combination with L-DOPA, 
significantly increased the number of TUNEL+ cells. This fact might contribute to the 
decreased number of newborn neurons detected in these two groups. About 30 000 
NPC migrate from the SVZ to the OB every day (Lledo et al., 2006). However, only 
half of them will reach the OB and differentiate into neuronal or glial phenotypes 
(Winner et al., 2002). The other NPC will undergo apoptosis during migration, or will 
be incapable to integrate into the neural circuitry of the OB. Selegiline is metabolized 
to amphetamine derivatives, which recently have been shown to inhibit the 
neuroprotective actions of both Selegiline and desmethyl selegiline in vivo (Jenner 
and Langston, 2011). The increase in amphetamine derivatives following Selegiline 
treatment have in fact recently been a matter of debate as potentially harmful (Yasar 
et al., 2006). This has, however, not been reported in PD patients. It is therefore 
possible that the decreased survival of NPC found in the OB after Selegiline 
treatment, reported in our study, may be influenced by the interaction with 
amphetamine derivatives, causing an increase in the number of TUNEL+ cells (Tian 
et al., 2009).  
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Evidence of a decreased number of NPC was also found in the OB in human 
postmortem tissue of PD patients compared to controls (Bedard and Parent, 2004; 
Höglinger et al., 2004; Liu and Martin, 2003). Due to different experimental methods, 
there are diverging opinions concerning the existence and structure of RMS and 
whether NPC migrate from the SVZ to the OB via a SVZ-RMS-OB route in the 
human brain (Curtis et al., 2007; Sanai et al., 2004).  
In order to investigate the neuronal fate of the NPC in the OB, the frequency of 
newborn BrdU+ cells co-stained with NeuN to confirm a neuronal phenotype, and 
with TH as a dopaminergic marker, was analyzed. The modulation of adult-born 
neurons was determined by the frequency of neuronal differentiation and the number 
of surviving NPC in the OB. We, and others, show that the frequency of neuronal 
differentiation is stably sustained in the GCL and PGL in both control and 6-OHDA 
lesioned animals (Winner et al., 2008; Winner et al., 2006). In addition, we show that 
L-DOPA and Selegiline treatment has no significant effect on the frequency of 
neuronal differentiation in the GCL and PGL. In regard to the number of surviving 
NPC and adult-born neurons, we show a substantial restoration following L-DOPA 
treatment, in line with the study of O'Keefee and colleagues (O'Keeffe et al., 2009b). 
The decreased number of surviving NPC and adult-born neurons after Selegiline 
treatment might be explained by a significant increase in TUNEL+ profiles. The 
effect of the combination of L-DOPA and Selegiline on the survival of NPC and 
adult-born neurons may rather suggest a modulation by the drug itself, than an effect 
of the elevated dopamine concentration in the OB.  
An increased number of dopamine neurons in the PGL of the OB in toxin-based 
animal models has previously been reported (Belzunegui et al., 2007; Winner et al., 
2008; Winner et al., 2006; Yamada et al., 2004). In this study we have investigated 
the effect of L-DOPA and Selegiline on the number of adult-born neurons, their 
dopaminergic differentiation and total number of dopaminergic neurons in the PGL of 
the OB. We show that dopaminergic differentiation is 2-fold higher and the number of 
adult-born dopaminergic neurons is increased after 6-OHDA-injection. We believe 
that our data show for the first time a differential modulation of L-DOPA and 
Selegiline on adult-born dopaminergic neurons in the PGL of the OB after dopamine 
depletion. L-DOPA seems to restore not only the survival of NPC, but also sustains a 
2-fold increase of dopaminergic differentiation (Table 2) and the pathological shift in 
the proportion of newborn dopamine neurons after 6-OHDA injection (Fig. 12C). 
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This might explain why L-DOPA treatment cannot only maintain, but even increase 
the total number of dopamine neurons. In contrast, the decreased number of surviving 
NPC and newborn neurons observed with Selegiline treatment, combined with a 
normal dopaminergic differentiation and neuronal proportion normalizes the 
upregulation of dopamine neurons (Fig. 12; Table 2).  
Although adult-born neurons in the OB are thought to relate to olfactory function, the 
impact of these adult-born neurons integrating into OB circuitry on functional 
outcome remains uncertain (Imayoshi et al., 2008; Jaskelioff et al., 2011; Lazarini et 
al., 2009; Mouret et al., 2009; Sakamoto et al., 2011). Dopamine neurons are one of 
the major subtypes of interneurons, which can be marked by TH in the PGL (Parrish-
Aungst et al., 2007). Our data suggest that the generation and differentiation of adult-
born dopamine neurons respond to pathological impacts (e.g. 6-OHDA) and 
pharmacological treatment.  
In patients, olfactory dysfunction is not improved by dopaminergic therapy (Quinn et 
al., 1987; Roth et al., 1998). An increased number of dopaminergic neurons can be 
seen in the PGL of the OB in postmortem studies of PD patients (Huisman et al., 
2004; Mundiñano et al., 2011a), with a conflicting report by Huisman and colleagues 
(Huisman et al., 2008). The increased number of inhibitory dopaminergic neurons in 
the PGL maintained by L-DOPA, but not Selegiline, in the current study might 
explain that olfactory dysfunction is still a common symptom in drug naïve PD 
patients and patients receiving L-DOPA therapy (Doty et al., 1992b).  
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2. Behavioral study	  
In this study, we discovered for the first time, a delayed olfactory deficit in an acute 
mouse model of intranigral 6-OHDA lesion. The olfactory deficit was reversed 
following long-term Selegiline treatment.  
The NOF assessment was used to evaluate general motor activity and the anxiety 
status of the animals by measuring the tracklength and the time spent in the central 
area of the arena. In our experimental design, wooden blocks were positioned in the 
central area (36.5 cm x 36.5 cm). The groups showed no severe motor deficits or 
anxiety, as the animals were able to perform the olfactory discrimination task in the 
central area. BilBX and Bil6OHDA showed a lower tracklength and time spent in the 
central area among groups. Comparing the results after 3 weeks and 12 weeks post op, 
the tracklength of the BilBX group was significantly decreased at 3 weeks post op, 
but there was no significant difference at 12 weeks post op compared to control, 
suggesting that the BilBX group might require a longer period to recover after the 
surgery compared to other groups. The surgery of bilateral bulbectomy showed local 
bleeding and edema, the disruption of the local blood supply together with retrograde, 
anterograde and transneuronal degeneration (Song and Leonard, 2005).  
Rat models of BilBX and Bil6OHDA were used to study anxiety and depression-like 
behavior (Rodriguez-Gaztelumendi et al., 2009; Tadaiesky et al., 2008). Olfactory 
bulbectomy caused not only anosmia but also a loss in detection of pheromones 
regulated by VNO and the accessory olfactory bulb, which connected to the amygdala 
and other brain areas, and were responsible for gender recognition, aggressive 
behavior and social dominance (Song and Leonard, 2005). It has been shown that in a 
Bil6OHDA rat floating time in the forced swim test increased and the time spent in 
the open arm of an elevated plus maze decreased, indicating an anhedonic-depressive 
like behavior (Tadaiesky et al., 2008). The group of Bil6OHDA showed the lowest 
duration spent in the central area at 3 weeks and 12 weeks post op, which might be 
related to depressive symptoms. However, the difference did not reach significance. 
There was no significant behavioral change in the mouse model of BilBX at 12 weeks 
post op in the current study, which might be due to species differences. 
After Selegiline treatment, the groups of Uni and UniC showed an increase, but no 
significant difference of the tracklength compared to control. The time spent in the 
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central area in all groups was slightly increased. These data might suggest that 
Selegiline has no effect on general motor activity. However, the increased time spent 
in the central area in all groups might be explained by the fact that Selegiline has an 
anxiolytic effect as shown in previous reports (Imamura et al., 2012; Riederer and 
Laux, 2011).     
In the 1st trial of odor discrimination, two wooden blocks carrying the animal's own 
odor were placed in the arena. Animals with normal olfactory function explored the 
whole arena and wooden blocks, where they spent approximately the same time on 
each wooden block. In the 2nd trial, one of the wooden blocks was replaced by one 
carrying another male's odor. The time spent at that block was slightly elevated. In the 
following trials (3rd to 5th), the time at the experimental block slowly decreased, 
which is called "habituation", caused by an elimination in part of mitral cells 
responding to an odor with increased firing rates in the absence of any paired 
reinforcement (Lazarini and Lledo, 2011). Moreover, habituation is required in non-
associative olfactory learning and short-term olfactory memory (Breton-Provencher et 
al., 2009). In the 6th trial, a wooden block scented the odor of a female was 
introduced; the duration of time at that wooden block increased significantly. The sex 
discrimination might be mixed regarding the function of the main OB and VNO 
system (Zufall and Leinders-Zufall, 2007). However, the olfactory discrimination of 
social odor in the groups of UniBX and BilBX (from 3 to 12 weeks post op) suggest 
that the main OB still plays a major role to identify odor of different genders. At 3 
weeks post op, the BilBX group was the only group, showing a deficit to discriminate 
odors. Olfactory bulbectomy in both sides (BilBX) might cause a destruction of the 
olfactory pathway from the olfactory epithelium to the olfactory cortex or higher brain 
areas. In contrast, the olfactory discrimination was preserved due to the intact 
olfactory bulb in the UniBX group, not different from control.  
An olfactory deficit in the UniC and Bil6OHDA was shown at 12 weeks post op (Fig. 
17), but not at 3 weeks post op,  which suggests a delayed effect of the pathological 
alteration to show as a behavioral impact. Even though there are no histological data 
to support at 12 weeks time point (refer to Part 1: Histological study), we have shown 
an impaired proliferation in the SVZ until 7 weeks post op.  Therefore we believe that 
there is no recovery in the SVZ after an intranigral 6-OHDA lesion (Fig. 8-9). 
Recently, a deficit of innate olfactory function was shown after NPC depletion with 
mice displaying behavioral deficits in male-male aggression and male sexual behavior 
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toward females (Masayuki Sakamoto, 2011). In the embryonic stage olfactory 
discrimination was clearly impaired by insufficient neurogenesis, but not later in 
adulthood (Lazarini and Lledo, 2011). We show for the first time in a 6-OHDA mouse 
model a delayed deficit of innate olfactory discrimination (male-female odors) at 12 
weeks post op, which suggests that innate odor discrimination is possibly related to 
abnormal NPC modulation in the OB after 6-OHDA lesion. 
In order to understand whether Selegiline can reverse the olfactory deficit shown in 
the UniC group, animals of all groups received Selegiline treatment for 12 weeks and 
the treatment was withdrawn thereafter for 4 weeks. The groups of control and UniBX 
still maintained a constant olfactory discrimination. However, the olfactory function 
of UniC, Bil6OHDA and BilBX groups was reversed after Selegiline treatment. But 
the groups showed again an olfactory deficit following Selegiline withdrawal. First, 
the data indicate that Selegiline has no impact on positive control groups, such as the 
control, Uni and UniBX, suggesting that a specific therapeutic effect of Selegiline, 
also in the case of a loss of olfactory discrimination cannot be detected in our 
experimental design. Second, in the groups of UniC, Bil6OHDA and BilBX olfactory 
dysfunction was recovered only by Selegiline treatment, suggesting a continuous and 
chronic therapeutic effect of Selegiline on olfactory function. In a recent report a 
complementary role of the main olfactory system and the vomeronasal system has 
been documented. Sensory nerves from the main OB and the VNO responded to 
social chemosignals and reacted with extraordinary high sensitivity in an overlapping 
manner (Brennan and Zufall, 2006). In our study, despite both main OB were 
removed surgically in the BilBX group (anterior parts from AP: +3.56 relative to 
bregma), parts of the accessory OB (posterior part from AP: +3.56 relative to bregma) 
were still remaining in the caudal part of the brain and the olfactory signal might 
possibly be reinforced and transferred via the vomeronasal neurons. Selegiline might 
increase the sensitivity and indirectly enlarge the signal transmission in the accessory 
OB-VNO system, which might replace the function of the main OB in the BilBX 
animals. This might explain an uncovered olfactory function in the BilBX group with 
Selegiline treatment. In the groups of UniC and Bil6OHDA the accessory OB-VNO 
system remained intact, therefore the effects of Selegiline treatment could be on NPC 
in the main OB and/or in the accessory OB-VNO system. A continuous and chronic 
Selegiline treatment can reverse an increased number of DA neurons in the PGL in 6-
OHDA lesioned animals, which might be the reason that the groups of UniC and 
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Bil6OHDA regained normal olfactory function. Moreover, Selegiline in addition 
might have an unknown effect on activating the accessory OB-VNO system. Further 
investigations are required to understand the details regarding the relationship 
between the effects of Selegiline on the main OB and the VNO system in 6-OHDA 
lesioned animals.  
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VI. Summary 
Hyposmia, often preceding the cardinal motor symptoms, such as bradykinesia, 
rigidity, tremor at rest and postural instability, is frequently reported in PD. This 
symptom appears to be related to an increased number of dopamine neurons in the 
periglomerular layer (PGL) of the OB. In the histological study, we have investigated 
the survival and neuronal differentiation of NPC in the OB, following L-DOPA 
and/or Selegiline in a unilateral, intranigral 6-OHDA lesion model in mice. Our data 
show that the number of NPC in the SVZ is decreased after 6-OHDA lesion, while 
there is no difference from control in lesioned mice with Selegiline or L-DOPA 
treatment. Moreover, the monoamine oxidase-B inhibitor, Selegiline, is able to 
normalize the number of dopamine neurons by increasing the number of TUNEL+ 
cell and reverses the dopaminergic differentiation to control in the PGL, while L-
DOPA treatment sustains the increased number, by increasing the survival of NPC 
and upregulating 2-fold dopaminergic differentiation observed in 6-OHDA lesioned 
animals. In the behavioral study, to understand the olfactory function after 6-OHDA 
lesion and the effects of Selegiline treatment, six different experimental groups were 
investigated and performed an olfactory discrimination test. The data show that a 
delayed olfactory deficit was first appeared 12 weeks post 6-OHDA lesion and the 
recovery of olfactory function followed a daily, chronic treatment of Selegiline for 
additional 12 weeks. However, the olfactory dysfunction of the animals relapses again 
after a 4-week withdrawal of Selegiline treatment.  
To combine the findings of our studies, we conclude that there is a distinct 
modulation of newly generated dopamine neurons of the OB after L-DOPA and/or 
Selegiline treatment. Furthermore, a delayed olfactory deficit was detected after a 
downregulation of adult neurogenesis, and only a chronic, continuous treatment of 
Selegiline can reverse the olfactory dysfunction in an acute mouse model of PD.  
Our findings provide practical implications and stimulate further clinical and 
preclinical research, bridging the basic knowledge of hyposmia of PD from bench to 
bedside. Although the relationship of hyposmia and an increased number of dopamine 
neurons in the OB of PD patients is not well defined yet, the evidence in this study 
may offer the explanation, that the dysregulation of adult neurogenesis might be one 
of reasons to cause hyposmia of PD. Moreover, the effects of Selegiline on olfactory 
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function could be a consideration for clinical application. However, further studies are 
needed to show whether the interaction of dopamine depletion and drug treatment 
plays a role in olfactory function in PD patients. 
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VII. Abbreviations 
6-OHDA    6-hydroxydopamine  
AADC     aromatic-L-amino-acid decarboxylase 
AP     antero-posterior 
AAV     adeno-associated virus 
Bil6OHDA    bilateral intranigral 6-OHDA injection 
BilBX     bilateral bulbectomy 
BrdU     bromodeoxyuridine  
DA     dopamine 
DAB     3,3´-diaminobenzidine 
DBS     deep brain stimulation 
DAergic    dopaminergic  
DG     dentate gyrus 
DV     dorso-ventral 
EGFR     epidermal growth factor receptor 
GABA     gamma aminobutyric acid 
GAD     glutamic acid decarboxylase 
GCL     granule cell layer  
GDNF     glial derived neurotropic factor 
GFAP     glial fibrillary acidic protein 
GFP     green fluorescence protein 
GPi     globus pallidus internus 
HPLC     high perfomance liquid chromatography  
iLBD     incidental Lewy body disease 
LB     Lewy bodies 
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L-DOPA    L-3,4-dihydroxyphenylalanine 
LN     Lewy neurites  
M/T cells    mitral and tufted cells 
MAO-A    monoamine oxidase-A 
MAO-B    monoamine oxidase-B  
MFB     median forebrain bundle 
ML     mediao-lateral 
MPTP     1-methyl-4phenyl-1,2,3,6-tetrahydropyridin 
MRI     magnetic resonance imaging 
NOF     novel open field 
NPC     neural progenitor cell  
OB     olfactory bulb 
ODT     olfactory discrimination test 
OSN     olfactory sensory neuron 
PB     phosphate buffer  
PCNA     proliferating cell nuclear antigen  
PD     Parkinson's disease  
PET     positron emission tomography 
PFA     paraformaldehyde 
PGL     periglomerular layer  
RBS     rapid eye movement sleep behavior disorder 
RMS     rostral migratory stream  
SGZ     subgranular zone 
SN     substantia nigra  
SSC     saline sodium citrate 
STN     subthalamic nucleus 
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STR     striatum 
SVZ     subventricular zone  
TF     transcriptional factor 
TH     tyrosine hydroxylase  
TUNEL    TdT-mediated dUTP-biotin nick end labeling. 
Uni     unilateral intranigral 6-OHDA injection 
UniBX     unilateral bulbectomy 
UniC     unilateral intranigral 6-OHDA injection plus 
     contralateral bulbectomy 
UPSIT     university of Pennsylvania smell identification 
     test 
VMAT2    vesicular monoamine transporter 2 
VNO     vomeronasal organ 
VTA     ventral tegmental area 
 
     
 
 
 
 
 
 
 
 
  
	   References	   	  
	   	  
72 
 
VIII. References 
Allen, Z. J., 2nd, Waclaw, R. R., Colbert, M. C., Campbell, K., 2007. Molecular 
identity of olfactory bulb interneurons: transcriptional codes of periglomerular 
neuron subtypes. J Mol Histol. 38, 517-25. 
 
Altman, J., 1969. Autoradiographic and histological studies of postnatal neurogenesis. 
IV. Cell proliferation and migration in the anterior forebrain, with special 
reference to persisting neurogenesis in the olfactory bulb. J. Comp. Neurol. 
137, 433-57. 
 
Altman, J., Das, G. D., 1965. Autoradiographic and histological evidence of postnatal 
hippocampal neurogenesis in rats. J Comp Neurol. 124, 319-35. 
 
Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Hoglinger, G. 
U., Oertel, W. H., Hartmann, A., 2008. Characterization of the striatal 6-
OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted 
mice. Exp Neurol. 210, 182-93. 
 
Ansari, K. A., Johnson, A., 1975. Olfactory function in patients with Parkinson's 
disease. J Chronic Dis. 28, 493-7. 
 
Antonini, A., Tolosa, E., Mizuno, Y., Yamamoto, M., Poewe, W. H., 2009. A 
reassessment of risks and benefits of dopamine agonists in Parkinson's disease. 
Lancet Neurol. 8, 929-37. 
 
Aungst, J. L., Heyward, P. M., Puche, A. C., Karnup, S. V., Hayar, A., Szabo, G., 
Shipley, M. T., 2003. Centre-surround inhibition among olfactory bulb 
glomeruli. Nature. 426, 623-9. 
 
Baker, H., Liu, N., Chun, H. S., Saino, S., Berlin, R., Volpe, B., Son, J. H., 2001. 
Phenotypic differentiation during migration of dopaminergic progenitor cells 
to the olfactory bulb. J Neurosci. 21, 8505-13. 
 
Baker, S. A., Baker, K. A., Hagg, T., 2004. Dopaminergic nigrostriatal projections 
regulate neural precursor proliferation in the adult mouse subventricular zone. 
Eur. J. Neurosci. 20, 575-79. 
 
Baker, S. A., Baker, K. A., Hagg, T., 2005. D3 dopamine receptors do not regulate 
neurogenesis in the subventricular zone of adult mice. Neurobiol Dis. 18, 523-
527. 
 
Bedard, A., Parent, A., 2004. Evidence of newly generated neurons in the human 
olfactory bulb. Brain Res. Dev. Brain Res. 151, 159-68. 
 
Belin, A. C., Westerlund, M., Anvret, A., Lindqvist, E., Pernold, K., Ogren, S. O., 
Duester, G., Galter, D., 2011. Modeling Parkinson's disease genetics: altered 
  
	   References	   	  
	   	  
73 
function of the dopamine system in Adh4 knockout mice. Behav Brain Res. 
217, 439-45. 
 
Belzunegui, S., San Sebastián, W., Garrido-Gil, P., Izal-Azcárate, A., Vázquez-
Claverie, M., López, B., Marcilla, I., Lanciego, J. L., Luquin, M.-R., 2007. 
The number of dopaminergic cells is increased in the olfactory bulb of 
monkeys chronically exposed to MPTP. Synapse. 61, 1006-12. 
 
Bohnen, N. I., Muller, M. L., Kotagal, V., Koeppe, R. A., Kilbourn, M. A., Albin, R. 
L., Frey, K. A., 2010. Olfactory dysfunction, central cholinergic integrity and 
cognitive impairment in Parkinson's disease. Brain. 133, 1747-54. 
 
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., Braak, E., 
2003. Staging of brain pathology related to sporadic Parkinson's disease. 
Neurobiol Aging. 24, 197-211. 
 
Brennan, P. A., Zufall, F., 2006. Pheromonal communication in vertebrates. Nature. 
444, 308-15. 
 
Breton-Provencher, V., Lemasson, M., Peralta, M. R., 3rd, Saghatelyan, A., 2009. 
Interneurons produced in adulthood are required for the normal functioning of 
the olfactory bulb network and for the execution of selected olfactory 
behaviors. J Neurosci. 29, 15245-57. 
 
Brill, M. S., Snapyan, M., Wohlfrom, H., Ninkovic, J., Jawerka, M., Mastick, G. S., 
Ashery-Padan, R., Saghatelyan, A., Berninger, B., Gotz, M., 2008. A dlx2- 
and pax6-dependent transcriptional code for periglomerular neuron 
specification in the adult olfactory bulb. J Neurosci. 28, 6439-52. 
 
Bronstein, J., Carvey, P., Chen, H., Cory-Slechta, D., DiMonte, D., Duda, J., English, 
P., Goldman, S., Grate, S., Hansen, J., Hoppin, J., Jewell, S., Kamel, F., 
Koroshetz, W., Langston, J. W., Logroscino, G., Nelson, L., Ravina, B., 
Rocca, W., Ross, G. W., Schettler, T., Schwarzschild, M., Scott, B., Seegal, 
R., Singleton, A., Steenland, K., Tanner, C. M., Van Den Eeden, S., 
Weisskopf, M., 2009. Meeting report: consensus statement-Parkinson's disease 
and the environment: collaborative on health and the environment and 
Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. 
Environ Health Perspect. 117, 117-21. 
 
Buck, L. B., Smell and Taste: The Chemical Senses. In: E. Kandel, et al., 4th Eds. 
Principles of Neural Science. McGraw-Hill Medical, New York, 2000, pp. 
625-36. 
 
Carleton, A., Rochefort, C., Morante-Oria, J., Desmaisons, D., Vincent, J. D., Gheusi, 
G., Lledo, P.-M., 2002. Making scents of olfactory neurogenesis. J. Physiol. 
Paris. 96, 115-22. 
 
Carlsson, T., Schindler, F. R., Hollerhage, M., Depboylu, C., Arias-Carrion, O., 
Schnurrbusch, S., Rosler, T. W., Wozny, W., Schwall, G. P., Groebe, K., 
Oertel, W. H., Brundin, P., Schrattenholz, A., Hoglinger, G. U., 2011a. 
  
	   References	   	  
	   	  
74 
Systemic administration of neuregulin-1beta1 protects dopaminergic neurons 
in a mouse model of Parkinson's disease. J Neurochem. 117, 1066-74. 
 
Curtis, M. A., Kam, M., Nannmark, U., Anderson, M. F., Axell, M. Z., Wikkelso, C., 
Holtas, S., van Roon-Mom, W. M., Bjork-Eriksson, T., Nordborg, C., Frisen, 
J., Dragunow, M., Faull, R. L., Eriksson, P. S., 2007. Human neuroblasts 
migrate to the olfactory bulb via a lateral ventricular extension. Science. 315, 
1243-9. 
 
Depboylu, C., Maurer, L., Matusch, A., Hermanns, G., Windolph, A., Béhé, M., 
Oertel, W.H., Höglinger, G.U., 2013. Effects of long-term treatment with 
pramipexole or levodopa on presynaptic markers assessed by longitudinal 123I 
FP-CIT SPECT and histochemistry. NeuroImage. 79, 191-200. 
 
Deumens, R., Blokland, A., Prickaerts, J., 2002. Modeling Parkinson's disease in rats: 
an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 
175, 303-17. 
 
Dickson, D. W., Fujishiro, H., DelleDonne, A., Menke, J., Ahmed, Z., Klos, K. J., 
Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Ahlskog, J. E., 2008. 
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's 
disease. Acta Neuropathol. 115, 437-44. 
 
Doetsch, F., Caille, I., Lim, D. A., Garcia-Verdugo, J. M., Alvarez-Buylla, A., 1999. 
Subventricular zone astrocytes are neural stem cells in the adult mammalian 
brain. Cell. 97, 703-16. 
 
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., 
Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., 
Tanner, C. M., 2007. Projected number of people with Parkinson disease in 
the most populous nations, 2005 through 2030. Neurology. 68, 384-6. 
 
Doty, R. L., Singh, A., Tetrud, J., Langston, J. W., 1992a. Lack of major olfactory 
dysfunction in MPTP-induced parkinsonism. Ann Neurol. 32, 97-100. 
 
Doty, R. L., Stern, M. B., Pfeiffer, C., Gollomp, S. M., Hurtig, H. I., 1992b. Bilateral 
olfactory dysfunction in early stage treated and untreated idiopathic 
Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 55, 138-42. 
 
Fahn, S., 2008. The history of dopamine and levodopa in the treatment of Parkinson's 
disease. Mov Disord. 23 Suppl 3, S497-508. 
 
Farrer, M. J., 2006. Genetics of Parkinson disease: paradigm shifts and future 
prospects. Nature Reviews Genetics. 7, 306-318. 
 
Fearnley, J. M., Lees, A. J., 1991. Ageing and Parkinson's disease: substantia nigra 
regional selectivity. Brain. 114 ( Pt 5), 2283-301. 
 
Fernandez, H. H., Chen, J. J., 2007. Monamine oxidase inhibitors: current and 
emerging agents for Parkinson disease. Clin. Neuropharmacol. 30, 150-168. 
 
  
	   References	   	  
	   	  
75 
Fleming, S. M., Tetreault, N. A., Mulligan, C. K., Hutson, C. B., Masliah, E., 
Chesselet, M. F., 2008. Olfactory deficits in mice overexpressing human 
wildtype alpha-synuclein. Eur J Neurosci. 28, 247-56. 
 
Freundlieb, N., Francois, C., Tande, D., Oertel, W. H., Hirsch, E. C., Hoglinger, G. 
U., 2006. Dopaminergic substantia nigra neurons project topographically 
organized to the subventricular zone and stimulate precursor cell proliferation 
in aged primates. J Neurosci. 26, 2321-5. 
 
Gage, F. H., 2000. Mammalian neural stem cells. Science. 287, 1433-8. 
 
Hack, M. A., Saghatelyan, A., de Chevigny, A., Pfeifer, A., Ashery-Padan, R., Lledo, 
P. M., Gotz, M., 2005. Neuronal fate determinants of adult olfactory bulb 
neurogenesis. Nat Neurosci. 8, 865-72. 
 
Hancock, D.B., Martin, E.R., Staijch, J.M., Jewett, R., Stacy, M.A., Scout, B.L. 2007. 
Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with 
Parkinson's disease. Arch. Neurol. 64, 576-580. 
 
Hirsch, E., Graybiel, A. M., Agid, Y. A., 1988. Melanized dopaminergic neurons are 
differentially susceptible to degeneration in Parkinson's disease. Nature. 334, 
345-8. 
 
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., 
Zalutsky, R., 2007. How common are the "common" neurologic disorders? 
Neurology. 68, 326-37. 
 
Höglinger, G. U., Rizk, P., Muriel, M. P., Duyckaerts, C., Oertel, W. H., Caille, I., 
Hirsch, E. C., 2004. Dopamine depletion impairs precursor cell proliferation in 
Parkinson disease. Nat. Neurosci. 7, 726-735. 
 
Hong, D.P., Fink, A.L., Uversky, V.N., 2009. Smoking and Parkinson's disease: does 
nicotine affect alpha-synuclein fibrillation ? Biochim. Biophys. Acta. 1794, 
282-290.  
 
Hsia, A. Y., Vincent, J. D., Lledo, P. M., 1999. Dopamine depresses synaptic inputs 
into the olfactory bulb. J. Neurophysiol. 82, 1082-1085. 
 
Huisman, E., Uylings, H. B. M., Hoogland, P. V., 2004. A 100% increase of 
dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's 
disease. Mov. Disord. 19, 687-692. 
 
Huisman, E., Uylings, H. B. M., Hoogland, P. V., 2008. Gender-related changes in 
increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease 
patients. Mov. Disord. 23, 1407-1413. 
 
Imamura, K., Okayasu, N., Nagatsu, T., 2012. Cerebral blood flow and freezing of 
gait in Parkinson's disease. Acta Neurol Scand. 126, 210-8. 
 
Imayoshi, I., Sakamoto, M., Ohtsuka, T., Takao, K., Miyakawa, T., Yamaguchi, M., 
Mori, K., Ikeda, T., Itohara, S., Kageyama, R., 2008. Roles of continuous 
  
	   References	   	  
	   	  
76 
neurogenesis in the structural and functional integrity of the adult forebrain. 
Nat. Neurosci. 11, 1153-1161. 
 
Jaskelioff, M., Muller, F. L., Paik, J.-H., Thomas, E., Jiang, S., Adams, A. C., Sahin, 
E., Kost-Alimova, M., Protopopov, A., Cadiñanos, J., Horner, J. W., Maratos-
Flier, E., Depinho, R. A., 2011. Telomerase reactivation reverses tissue 
degeneration in aged telomerase-deficient mice. Nature. 469, 102-106. 
 
Jenner, P., Langston, J. W., 2011. Explaining ADAGIO: a critical review of the 
biological basis for the clinical effects of rasagiline. Mov. Disord. 26, 2316-
23. 
 
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., Pearce, R. K., 2009. Parkinson 
disease: extranigral, multisystem, and {alpha}-synuclein "plus". Arch Neurol. 
66, 914-5; author reply 915-6. 
 
Kandel, E., Schwartz, J., Jessell, T., 2000. Principles of Neural Science. McGraw-Hill 
Medical. 
 
Kaplan, M. S., Hinds, J. W., 1977. Neurogenesis in the adult rat: electron microscopic 
analysis of light radioautographs. Science. 197, 1092-4. 
 
Kempermann, G., 2011. Seven principles in the regulation of adult neurogenesis. Eur 
J Neurosci. 33, 1018-24. 
 
Kirik, D., Rosenblad, C., Bjorklund, A., 1998. Characterization of behavioral and 
neurodegenerative changes following partial lesions of the nigrostriatal 
dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp 
Neurol. 152, 259-77. 
 
Kuhn, H. G., Biebl, M., Wilhelm, D., Li, M., Friedlander, R. M., Winkler, J., 2005. 
Increased generation of granule cells in adult Bcl-2-overexpressing mice: a 
role for cell death during continued hippocampal neurogenesis. Eur. J. 
Neurosci. 22, 1907-1915. 
 
Lang, A. E., 2011. A critical appraisal of the premotor symptoms of Parkinson's 
disease: potential usefulness in early diagnosis and design of neuroprotective 
trials. Mov Disord. 26, 775-83. 
 
Langston, J. W., Ballard, P. A., Jr., 1983. Parkinson's disease in a chemist working 
with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med. 309, 310. 
 
Lazarini, F., Lledo, P. M., 2011. Is adult neurogenesis essential for olfaction? Trends 
Neurosci. 34, 20-30. 
 
Lazarini, F., Mouthon, M.-A., Gheusi, G., de Chaumont, F., Olivo-Marin, J.-C., 
Lamarque, S., Abrous, D. N., Boussin, F. D., Lledo, P.-M., 2009. Cellular and 
behavioral effects of cranial irradiation of the subventricular zone in adult 
mice. PLoS ONE. 4, e7017. 
 
  
	   References	   	  
	   	  
77 
Lim, S. Y., Fox, S. H., Lang, A. E., 2009. Overview of the extranigral aspects of 
Parkinson disease. Arch Neurol. 66, 167-72. 
 
Lindvall, O., Kokaia, Z., 2010. Stem cells in human neurodegenerative disorders--
time for clinical translation? J Clin Invest. 120, 29-40. 
 
Liu, Z., Martin, L. J., 2003. Olfactory bulb core is a rich source of neural progenitor 
and stem cells in adult rodent and human. J. Comp. Neurol. 459, 368-91. 
 
Lledo, P.-M., Alonso, M., Grubb, M. S., 2006. Adult neurogenesis and functional 
plasticity in neuronal circuits. Nat. Rev. Neurosci. 7, 179-193. 
 
Lo, S. E., Jain, S., 2006. Patient page. Slowing down a "slow" movement disorder: 
selegiline's benefit in treating Parkinson disease. Neurology. 66, E28-9. 
 
Lois, C., Alvarez-Buylla, A., 1994. Long-distance neuronal migration in the adult 
mammalian brain. Science 264, 1145-1148. 
 
Ma, S. Y., Roytta, M., Rinne, J. O., Collan, Y., Rinne, U. K., 1997. Correlation 
between neuromorphometry in the substantia nigra and clinical features in 
Parkinson's disease using disector counts. J Neurol Sci. 151, 83-7. 
 
Magyar, K., 2004. (−)-Deprenyl, A Selective MAO-B Inhibitor, with Apoptotic and 
Anti-apoptotic Properties. NeuroToxicology. 25, 233-242. 
 
Mandairon, N., Sultan, S., Nouvian, M., Sacquet, J., Didier, A., 2011. Involvement of 
newborn neurons in olfactory associative learning? The operant or non-
operant component of the task makes all the difference. J Neurosci. 31, 12455-
60. 
 
Marsden, C. D., 1990. Parkinson's disease. Lancet. 335, 948-52. 
 
Marxreiter, F., Nuber, S., Kandasamy, M., Klucken, J., Aigner, R., Burgmayer, R., 
Couillard-Despres, S., Riess, O., Winkler, J., Winner, B., 2009. Changes in 
adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of 
alpha-synuclein. Eur J Neurosci. 29, 879-90. 
 
Masayuki Sakamoto, I. I. T. O. M. Y. K. M. a. R. K., 2011. Continuous neurogenesis 
in the adult forebrain is required for innate olfactory responses. PNAS. 1-6. 
 
Ming, G.-L. and Song, H., 2011. Adult neurogensis in the mammalian brain: 
Significant answers and significant questions. Neuron. 70, 687-702. 
 
Mouret, A., Lepousez, G., Gras, J., Gabellec, M.-M., Lledo, P.-M., 2009. Turnover of 
newborn olfactory bulb neurons optimizes olfaction. J. Neurosci. 29, 12302-
12314. 
 
Mundiñano, I.-C., Caballero, M.-C., Ordóñez, C., Hernandez, M., DiCaudo, C., 
Marcilla, I., Erro, M.-E., Tuñon, M.-T., Luquin, M.-R., 2011 Increased 
dopaminergic cells and protein aggregates in the olfactory bulb of patients 
with neurodegenerative disorders. Acta Neuropathol. 122, 61-74. 
  
	   References	   	  
	   	  
78 
 
Nottebohm, F., 2004. The road we travelled: discovery, choreography, and 
significance of brain replaceable neurons. Ann N Y Acad Sci. 1016, 628-58. 
 
O'Keeffe, G. C., Barker, R. A., Caldwell, M. A., 2009a. Dopaminergic modulation of 
neurogenesis in the subventricular zone of the adult brain. Cell Cycle. 8, 2888-
2894. 
 
O'Keeffe, G. C., Tyers, P., Aarsland, D., Dalley, J. W., Barker, R. A., Caldwell, M. 
A., 2009b. Dopamine-induced proliferation of adult neural precursor cells in 
the mammalian subventricular zone is mediated through EGF. Proc. Natl. 
Acad. Sci. USA. 106, 8754-8759. 
 
Ono, K., Hirohata, M., Yamada, M., 2007. Anti-fibrillogenic and fibril-destabilizing 
activity of nicotine in vitro: implications for the prevention and therapeutics of 
Lewy body disease. Exp. Neurol. 205, 414-424. 
 
O'Sullivan, S. S., Johnson, M., Williams, D. R., Revesz, T., Holton, J. L., Lees, A. J., 
Perry, E. K., 2011. The effect of drug treatment on neurogenesis in Parkinson's 
disease. Mov. Disord. 26, 45-50. 
 
Pakkenberg, B., Moller, A., Gundersen, H. J., Mouritzen Dam, A., Pakkenberg, H., 
1991. The absolute number of nerve cells in substantia nigra in normal 
subjects and in patients with Parkinson's disease estimated with an unbiased 
stereological method. J Neurol Neurosurg Psychiatry. 54, 30-3. 
 
Pålhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-Ikola, O., Palm, R., 
2006. Selegiline slows the progression of the symptoms of Parkinson disease. 
Neurology. 66, 1200-6. 
 
Pålhagen, S., Heinonen, E. H., Hagglund, J., Kaugesaar, T., Kontants, H., Maki-Ikola, 
O., Palm, R., Turunen, J., 1998. Selegiline delays the onset of disability in de 
novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 51, 
520-5. 
 
Parkinson, J., 2002. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin 
Neurosci. 14, 223-36. 
 
Parrish-Aungst, S., Shipley, M. T., Erdelyi, F., Szabo, G., Puche, A. C., 2007. 
Quantitative analysis of neuronal diversity in the mouse olfactory bulb. J. 
Comp. Neurol. 501, 825-36. 
 
Poewe, W., 2009. Treatments for Parkinson disease--past achievements and current 
clinical needs. Neurology. 72, S65-73. 
 
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., 
Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., 
Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. 
G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., Nussbaum, R. 
L., 1997. Mutation in the alpha-synuclein gene identified in families with 
Parkinson's disease. Science. 276, 2045-7. 
  
	   References	   	  
	   	  
79 
 
Prediger, R. D., Rial, D., Medeiros, R., Figueiredo, C. P., Doty, R. L., Takahashi, R. 
N., 2009. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci. 
1170, 629-36. 
 
Quinn, N. P., Rossor, M. N., Marsden, C. D., 1987. Olfactory threshold in Parkinson's 
disease. J. Neurol. Neurosurg. Psychiatry. 50, 88-9. 
 
Rascol, O., Lozano, A., Stern, M., Poewe, W., 2011. Milestones in Parkinson's 
disease therapeutics. Mov Disord. 26, 1072-82. 
 
Riederer, P., Laux, G., 2011. MAO-inhibitors in Parkinson's Disease. Exp Neurobiol. 
20, 1-17. 
 
Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M. J., 
Kholodilov, N., Burke, R. E., 2006. Oncoprotein Akt/PKB induces trophic 
effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 
103, 18757-62. 
 
Rochefort, C., Gheusi, G., Vincent, J. D., Lledo, P. M., 2002. Enriched odor exposure 
increases the number of newborn neurons in the adult olfactory bulb and 
improves odor memory. J Neurosci. 22, 2679-89. 
 
Rodriguez-Gaztelumendi, A., Rojo, M. L., Pazos, A., Diaz, A., 2009. Altered CB 
receptor-signaling in prefrontal cortex from an animal model of depression is 
reversed by chronic fluoxetine. J Neurochem. 108, 1423-33. 
 
Ross, G. W., Abbott, R. D., Petrovitch, H., Morens, D. M., Grandinetti, A., Tung, K. 
H., Tanner, C. M., Masaki, K. H., Blanchette, P. L., Curb, J. D., Popper, J. S., 
White, L. R., 2000. Association of coffee and caffeine intake with the risk of 
Parkinson disease. JAMA. 283, 2674-9. 
 
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., 
Launer, L., White, L. R., 2008. Association of olfactory dysfunction with risk 
for future Parkinson's disease. Ann Neurol. 63, 167-73. 
 
Roth, J., Radil, T., Ruzicka, E., Jech, R., Tichy, J., 1998. Apomorphine does not 
influence olfactory thresholds in Parkinson's disease. Funct. Neurol. 13, 99-
103. 
 
Sakamoto, M., Imayoshi, I., Ohtsuka, T., Yamaguchi, M., Mori, K., Kageyama, R., 
2011. Continuous neurogenesis in the adult forebrain is required for innate 
olfactory responses. Proc. Natl. Acad. Sci. USA. 108, 8479-84. 
 
Sanai, N., Tramontin, A. D., Quinones-Hinojosa, A., Barbaro, N. M., Gupta, N., 
Kunwar, S., Lawton, M. T., McDermott, M. W., Parsa, A. T., Manuel-Garcia 
Verdugo, J., Berger, M. S., Alvarez-Buylla, A., 2004. Unique astrocyte ribbon 
in adult human brain contains neural stem cells but lacks chain migration. 
Nature. 427, 740-4. 
 
  
	   References	   	  
	   	  
80 
Sanchez-Andrade, G., Kendrick, K. M., 2009. The main olfactory system and social 
learning in mammals. Behav Brain Res. 200, 323-35. 
 
Schwarting, R. K., Huston, J. P., 1996. Unilateral 6-hydroxydopamine lesions of 
meso-striatal dopamine neurons and their physiological sequelae. Prog 
Neurobiol. 49, 215-66. 
 
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J. F., Morelli, M., 2006. Targeting 
adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 29, 647-54. 
 
Shipley, M. T., Ennis, M., 1996. Functional organization of olfactory system. J 
Neurobiol. 30, 123-76. 
 
Song, C., Leonard, B. E., 2005. The olfactory bulbectomised rat as a model of 
depression. Neurosci Biobehav Rev. 29, 627-47. 
 
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., Goedert, 
M., 1997. Alpha-synuclein in Lewy bodies. Nature. 388, 839-40. 
 
Suh, H., Deng, W., Gage, F. H., 2009. Signaling in adult neurogenesis. Annu Rev Cell 
Dev Biol. 25, 253-75. 
 
Sui, Y., Horne, M. K., Stanic, D., 2012. Reduced proliferation in the adult mouse 
subventricular zone increases survival of olfactory bulb interneurons. PLoS 
One. 7, e31549. 
 
Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P., Cargnin-Ferreira, E., Da 
Cunha, C., Takahashi, R. N., 2008. Emotional, cognitive and neurochemical 
alterations in a premotor stage model of Parkinson's disease. Neuroscience. 
156, 830-40. 
 
Tanner, C.M., Goldman, S.M., Aston, D.A., Ottman, R., Ellenberg, J., Mayeux, R., 
2002. Smoking and Parkinson's disease in twins. Neurology. 58, 581-588 
 
Taylor, T. N., Caudle, W. M., Shepherd, K. R., Noorian, A., Jackson, C. R., Iuvone, 
P. M., Weinshenker, D., Greene, J. G., Miller, G. W., 2009. Nonmotor 
symptoms of Parkinson's disease revealed in an animal model with reduced 
monoamine storage capacity. J Neurosci. 29, 8103-13. 
 
The Parkinson Study Group, 1993. Effects of tocopherol and deprenyl on the 
progression of disability in early Parkinson's disease. The Parkinson Study 
Group. N. Engl. J. Med. 328, 176-83. 
 
Tian, C., Murrin, L. C., Zheng, J. C., 2009. Mitochondrial fragmentation is involved 
in methamphetamine-induced cell death in rat hippocampal neural progenitor 
cells. PLoS One. 4, e5546. 
 
Tillerson, J. L., Caudle, W. M., Parent, J. M., Gong, C., Schallert, T., Miller, G. W., 
2006. Olfactory discrimination deficits in mice lacking the dopamine 
transporter or the D2 dopamine receptor. Behav Brain Res. 172, 97-105. 
 
  
	   References	   	  
	   	  
81 
Ubeda-Bañon, I., Saiz-Sanchez, D., de la Rosa-Prieto, C., Argandoña-Palacios, L., 
Garcia-Muñozguren, S., Martinez-Marcos, A., 2010. alpha-Synucleinopathy in 
the human olfactory system in Parkinson's disease: involvement of calcium-
binding protein- and substance P-positive cells. Acta neuropathologica. 119, 
723-735. 
 
Ungerstedt, U., 1968. 6-Hydroxy-dopamine induced degeneration of central 
monoamine neurons. Eur J Pharmacol. 5, 107-10. 
 
van den Berge, S. A., van Strien, M. E., Korecka, J. A., Dijkstra, A. A., Sluijs, J. A., 
Kooijman, L., Eggers, R., De Filippis, L., Vescovi, A. L., Verhaagen, J., van 
de Berg, W. D., Hol, E. M., 2011. The proliferative capacity of the 
subventricular zone is maintained in the parkinsonian brain. Brain. 134, 3249-
63. 
 
Van Kampen, J. M., Hagg, T., Robertson, H. A., 2004. Induction of neurogenesis in 
the adult rat subventricular zone and neostriatum following dopamine D3 
receptor stimulation. Eur. J. Neurosci. 19, 2377-87. 
 
Wachowiak, M., Shipley, M. T., 2006. Coding and synaptic processing of sensory 
information in the glomerular layer of the olfactory bulb. Seminars in cell & 
developmental biology. 17, 411-423. 
 
Winner, B., Cooper-Kuhn, C. M., Aigner, R., Winkler, J., Kuhn, H. G., 2002. Long-
term survival and cell death of newly generated neurons in the adult rat 
olfactory bulb. Eur. J. Neurosci. 16, 1681-1689. 
 
Winner, B., Couillard-Despres, S., Geyer, M., Aigner, R., Bogdahn, U., Aigner, L., 
Kuhn, H. G., Winkler, J., 2008. Dopaminergic lesion enhances growth factor-
induced striatal neuroblast migration. J. Neuropathol. Exp. Neurol. 67, 105-
116. 
 
Winner, B., Desplats, P., Hagl, C., Klucken, J., Aigner, R., Ploetz, S., Laemke, J., 
Karl, A., Aigner, L., Masliah, E., Buerger, E., Winkler, J., 2009. Dopamine 
receptor activation promotes adult neurogenesis in an acute Parkinson model. 
Exp. Neurol. 219, 543-552. 
 
Winner, B., Geyer, M., Couillard-Despres, S., Aigner, R., Bogdahn, U., Aigner, L., 
Kuhn, G., Winkler, J., 2006. Striatal deafferentation increases dopaminergic 
neurogenesis in the adult olfactory bulb. Exp. Neurol. 197, 113-121. 
 
Wirdefeldt, K., Adami, H. O., Cole, P., Trichopoulos, D., Mandel, J., 2011. 
Epidemiology and etiology of Parkinson's disease: a review of the evidence. 
Eur J Epidemiol. 26 Suppl 1, S1-58. 
 
Witt, M., Bormann, K., Gudziol, V., Pehlke, K., Barth, K., Minovi, A., Hähner, A., 
Reichmann, H., Hummel, T., 2009. Biopsies of olfactory epithelium in 
patients with Parkinson's disease. Movement disorders : official journal of the 
Movement Disorder Society. 24, 906-914. 
 
  
	   References	   	  
	   	  
82 
Yamada, M., Onodera, M., Mizuno, Y., Mochizuki, H., 2004. Neurogenesis in 
olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience. 124, 173-
81. 
 
Yasar, S., Justinova, Z., Lee, S.-H., Stefanski, R., Goldberg, S. R., Tanda, G., 2006. 
Metabolic transformation plays a primary role in the psychostimulant-like 
discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]. J. Pharmacol. 
Exp. Ther. 317, 387-394. 
 
Young, S. Z., Taylor, M. M., Bordey, A., 2011. Neurotransmitters couple brain 
activity to subventricular zone neurogenesis. Eur J Neurosci. 33, 1123-32. 
 
Zufall, F., Leinders-Zufall, T., 2007. Mammalian pheromone sensing. Curr Opin 
Neurobiol. 17, 483-9. 
 
 
 
   
	   Acknowledgement	   	  
	   	  
83 
 
IX. Acknowledgement 
First, I would like to thank my thesis supervisor, PD Dr. Vincent Ries, for his 
guidance and support of my doctoral studies with a lot of patience and scope for 
development, helping me to finish my projects and thesis. 
 
Second, I would like to thank Prof. Wolfgang Oertel and Prof. Günter Höglinger, 
accepting my application. Also, I thank them for providing the facilities at the 
department of Neurology, but also for their comments and suggestions on my project. 
 
Third, I would like to thank Mrs. Silke Caspari and Miss Sabine Anfimov for the 
excellent technical assistance, including tissue processing and histological staining.  
 
Last but not least, I would like to thank my family and friends in Taiwan, always 
supporting me during my studies in Germany. I also appreciate the friends I met in 
Germany, who always encouraged me to go on in rainy days.  
 
  
	   Verzeichnis	  der	  akademischen	  Lehrer	   	  
	   	  
84 
X. Verzeichnis der akademischen Lehrer	  
  
 
Meine akademischen Lehrer waren die Damen/ Herren, 
 
Univ.-Prof. Dr. Aigner  Institut für Molekulare Regenerative Medizin 
     Paracelsus Medizinische Universität, Salzburg 
Doz. Dr. Couillard-Despres  Institut für Molekulare Regenerative Medizin 
     Paracelsus Medizinische Universität, Salzburg 
Prof. Dr. Grennlee   Institut für Experimentelle Psychologie 
     Universität Regensburg 
Prof. Dr. Helfrich-Förster  Biologie und Vorklinische Medizin,    
     Institut für Zologie, Universität Regensburg 
Dr. Navarro    Biologie und Vorklinische Medizin,    
     Institut für Zologie, Universität Regensburg 
Prof. Dr. Neumann   Biologie und Vorklinische Medizin,    
     Institut für Zologie, Universität Regensburg 
Dr. Rivera    Institut für Molekulare Regenerative Medizin 
     Paracelsus Medizinische Universität, Salzburg 
Prof. Dr. Schneuwly   Biologie und Vorklinische Medizin,    
     Institut für Zologie, Universität Regensburg 
Prof. Dr. Wekerle    Max-Planck Institut für Neurobiologie 
      
  
 
 
  
	   Ehrenwörtliche	  Erklärung	   	  
	   	  
85 
 
XI. Ehrenwörtliche Erklärung 
Ich erkläre ehrenwörtlich, dass ich die dem Fachbereich Medizin Marburg zur 
Promotionsprüfung eingereichte Arbeit mit dem Titel "Modulation of Adult 
Neurogenesis in the Olfactory Bulb in an Acute Mouse Model of Parkinson's Disease" 
in der Klinik für Neurologie unter der Leitung von Prof. Dr. Oertel und PD Dr. Ries 
ohne sonstige Hilfe selbst durchgeführt und bei der Abfassung der Arbeit keine 
anderen als die in der Dissertation aufgeführten Hilfsmittel benutzt habe. Ich habe 
bisher an keinem in- oder ausländischen medizinischen Fachbereich ein Gesuch um 
Zulassung zur Promotion eingereicht, noch die vorliegende oder eine andere Arbeit 
als Dissertation vorgelegt. 
 
 
 
 
 
 
 
Marburg, den 
 
Wei-Hua CHIU
  86 
 
